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Abstract 
SH-SY5Y neuroblastoma cells have been widely used in neuroscience research to 
model neurotoxic processes. It is unclear how well, in their undifferentiated, 
immortalised state, the cells model the original tissue type. SH-SY5Y cells can be 
differentiated, with compounds such as retinoic acid (RA), to become more ‘tissue-
like’, and potentially better reflect the biochemistry of a mature neuronal cell. Studies 
that have investigated the RA-induced differentiation process have focused on upstream 
changes associated with a small number of genes or proteins. This study proposed to use 
a novel approach in untargeted gas chromatography-mass spectrometry (GC-MS) 
metabolomic analysis to investigate the downstream biochemical changes in the 
metabolome, which are closer to the phenotype associated with an RA-differentiated 
cell. Metabolomics was utilised to profile a wide range of biochemical changes in SH-
SY5Y cells exposed to RA and how these processes were affected by exposure to 
malaoxon, a toxic metabolite of the pesticide malathion, to assess whether differentiated 
cells are more appropriate in future toxicology research.  
Cultured human SH-SY5Y neuroblastoma cells were exposed to 10 µM RA for 120 
hours and 1 µM malaoxon for 24 hours. The samples were quenched, harvested, 
extracted and derivatised before metabolomic analysis was carried out using untargeted 
GC-MS. The metabolites that contributed most to the variance were identified using 
principal component analysis. This indicated that RA-differentiated cells, and 
undifferentiated and differentiated cells exposed to malaoxon, were grouped in relation 
to metabolite profile. The important metabolites were subsequently analysed to 
determine changes due to RA and malaoxon exposure, with the aim to produce a profile 
of RA-differentiation cells and of the differential toxicity between undifferentiated and 
differentiated cells.  
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Changes were profiled in a range of metabolites including amino acids, carbohydrates, 
fatty acids and unknowns, indicating that exposure to RA caused a biochemical 
response in relation to neurite outgrowth, survival and apoptosis, decreased energy 
demand for cell proliferation and increased synthesis and activation of proteins involved 
in cell signalling. Data suggest that exposure to malaoxon induced a glutamate-
mediated excitotoxic response causing oxidative stress, mitochondrial dysfunction, 
energy depletion and damage to the cell membrane. In the differentiated state, induction 
of survival and apoptotic responses may have facilitated a neuroprotective response that 
decreased the toxic effects of malaoxon.  
This preliminary study has demonstrated that GC-MS-based metabolomic analysis can 
be used to detect changes in metabolite profile after RA and malaoxon exposure, 
illustrating the efficacy of this technique. The data indicates that there were a range of 
biochemical changes associated with an RA differentiated phenotype and that using 
such cells to study the effects of neurotoxins should be done with caution due to the 
potential neuroprotective response. The outcomes of this study have implications for 
research using RA-differentiated SH-SY5Y cells, with the decision to use differentiated 
cells resting on the particular neurotoxic model being investigated.  
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Figure 1.1 Structure of a 
neuron including cell body, 
dendrites, axon, axon terminal 
and synapse. Sourced from 
(Rhoades 2012). 
1. Introduction 
1.1 Nervous system and neurotransmission  
Neurons are the key structural and functional elements of the nervous system allowing 
for rapid transmission of electrochemical signals (Johnson 2011, Rhoades 2012). As 
seen in Figure 1.1, a neuron is composed of the soma (cell body), dendrites that receive 
incoming information, and axons which transmit information received from dendrites or 
the cell body by way of an action potential (Johnson 2011, Rhoades 2012). An action 
potential is a temporary depolarisation and repolarisation of the membrane initiated at 
the axon hillock (Johnson 2011, Rhoades 2012). Axons 
can be protected by an insulating myelin sheath  produced 
by Schwann cells, which allows for rapid conduction of 
action potentials down the axon between the nodes of 
Ranvier (Johnson 2011, Rhoades 2012). Transmission of 
the signal between nerves occurs at a synapse in the 
terminal region of the axon which stores 
neurotransmitters that are released into the synaptic cleft 
due to an incoming action potential (Figure 1.2) (Johnson 
2011, Newton 2012, Rhoades 2012). The action potential 
causes depolarisation and opening of voltage-gated 
calcium (Ca
2+
) channels allowing Ca
2+
 to flow into the 
cell resulting in neurotransmitter-vesicles fusing with the 
pre-synaptic membrane (Rhoades 2012). This releases neurotransmitter molecules into 
the synaptic cleft which bind to receptors in the postsynaptic membrane, causing 
depolarisation (Figure 1.3) (Johnson 2011, Rhoades 2012). In an unstimulated state, 
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neurons have a resting membrane potential of approximately  -70 mV, and both sodium 
(Na
+
) and potassium (K
+
) gated ion channels on the cell membrane remain closed 
(Johnson 2011, Newton 2012, Rhoades 2012). For a neuron to go from resting state to 
formation of an action potential, a threshold membrane depolarisation has to be attained 
(Johnson 2011, Newton 2012, Rhoades 2012). When threshold is reached, the 
depolarisation phase occurs causing Na
+
 channels to open, allowing an influx of Na
+
 
into the cell (Rhoades 2012). K
+
 channels remain closed until the peak of the action 
potential is reached (Johnson 2011, Newton 2012, Rhoades 2012). At the peak, Na
+
 
channels close and K
+
 gated channels open causing an efflux of K
+
 and repolarisation, 
followed by return to the resting state (Johnson 2011, Newton 2012, Rhoades 2012).  
Acetylcholine (ACh) is a common neurotransmitter that requires acetylcholinesterase 
(AChE) in the cholinergic synapse to hydrolyse the molecule (Rhoades 2012). When 
released into the synaptic cleft, ACh binds to two types of post-synaptic membrane 
cholinergic receptors: nicotinic and muscarinic receptors (Figure 1.4). Nicotinic 
receptors are ligand-gated ion channels composed of 5 subunits designed to trigger 
Figure 1.3 An action potential travels along 
the axon in a wave of depolarisation. Sourced 
from (Rhoades 2012). 
Figure 1.2 Arrival of an action potential at a 
synapse in the axon terminal. Sourced from 
(Rhoades 2012). 
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Figure 1.4 Arrival of an action potential at 
a cholinergic synapse. Sourced from 
(Rhoades 2012). 
rapid neuronal transmissions (Pope 1999, Rhoades 2012). When ACh binds, it causes a 
conformational change allowing entry of Na
+
 and subsequent depolarisation of the post-
synaptic cell (Pope 1999, Rhoades 2012). Muscarinic receptors belong to the G protein-
coupled receptor (GPCR) family, and have 5 sub-types (M1-M5) (Pope 1999, Rhoades 
2012). When ACh binds it causes a conformational change in the receptor activating the 
intracellular G protein which can then activate downstream intracellular events.  
1.1.1 Malathion and malaoxon 
Organophosphorus (OP) pesticides have been used for over 50 years to control pests for 
agriculture, domestic and vector use (Krstic et al. 2008, Pope 1999, Roberts and Aaron 
2007). Although the use of OP pesticides is beneficial, there is an increasing worldwide 
problem of acute poisoning as OP pesticides cause >200,000 deaths per year in 
developing countries (Roberts and Aaron 2007).  
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Figure 1.5 Chemical structure of the organophosphorus pesticide malathion and its toxic metabolite 
malaoxon. Obtained from (ChemSpider 2015). 
Malathion Malaoxon 
The OP pesticides are a diverse group of cholinesterase inhibitors, eliciting their effect 
by targeting the normal functioning of neurons and the nervous system. (dos Santos et 
al. 2011, Eddleston et al. 2008, Krstic et al. 2008, Roberts and Aaron 2007).  
Malathion is an OP pesticide and an irreversible AChE inhibitor, and compared to other 
pesticides of this type, has relatively low acute mammalian toxicity (SRC 2003). Use of 
malathion in the environment can cause contamination of water, soil, plants and other 
surfaces that can lead to human exposure, however it does not persist in the 
environment for long periods of time and is usually broken down within a few weeks 
(Krstic et al. 2008, SRC 2003). Exposure to malathion can occur through inhalation, 
ingestion and via the skin by which it can rapidly enter the bloodstream and potentially 
cause poisoning or even death (SRC 2003). Of the malathion that enters the 
bloodstream, most is metabolised by the liver where hydrolysis mainly takes place and 
the products are excreted in the urine. A small proportion of malathion however, can 
undergo oxidation to produce the metabolite malaoxon which is approximately 100 
times more toxic than the parent compound, and causes most of the systemic effects 
seen with malathion exposure including AChE inhibition (Figure 1.5) (dos Santos et al. 
2011, Krstic et al. 2008, SRC 2003).  
5 
 
The similarity of malaoxon to the neurotransmitter ACh is responsible for the 
inhibition; malaoxon blocks AChE by binding to the serine residue at its active site 
causing a displacement reaction, resulting in dimethyl-phosphorylated AChE (Pope 
1999, SRC 2003). This inhibits the ability of the enzyme to bind and thus hydrolyse 
ACh, resulting in ACh accumulation in cholinergic nerve synapses and overstimulation 
of the post-synaptic cell. This hyperexcitation can affect both the peripheral and central 
nervous systems (Eddleston et al. 2008, Roberts and Aaron 2007, SRC 2003).  
Signs and symptoms of AChE inhibitor poisoning can vary between individuals 
depending on age, dose and route of exposure, but can potentially result in multisystem 
toxicity and death (Roberts and Aaron 2007). Effects of OP exposure can include acute 
toxic effects due to AChE inhibition, but also involve low level chronic exposure which 
can induce numerous diseases in relation to the nervous and immune systems (Krstic et 
al. 2008). Accumulation of ACh at muscarinic receptors can result in bradycardia, 
bronchoconstriction, bronchorrhoea, cardiac arrhythmias, diarrhoea, hypotension, 
lacrimation and salivation (Eddleston et al. 2008, Roberts and Aaron 2007, SRC 2003). 
At nicotinic receptors, ACh accumulation can result in hypertension, muscle 
fasciculation and weakness potentially resulting in paralysis and respiratory failure, and 
tachycardia (Eddleston et al. 2008, Roberts and Aaron 2007, SRC 2003). General 
effects on the central nervous system (CNS) include respiratory failure and seizures 
(Roberts and Aaron 2007).  
1.2 Immortalised cell lines 
Cultured cells are an essential tool in studying the biochemical mechanisms of 
toxicology and the use of in vitro models that represent mature neurons are crucial in 
order to accurately reflect these mechanisms. However, obtaining cells directly from a 
6 
 
human source (primary cells) has many problems, including ethical considerations and 
the requirement for specialised culture conditions (Agholme et al. 2010). Immortalised, 
or continuous cell lines, are an effective alternative to primary cells as they can be 
derived from human tissue and are homogeneous, whereas primary cell cultures are 
characterised by heterogeneity (Tieu et al. 1999). Another key advantage of the use of 
these cell lines is that they are oncogenic and therefore mitotic, so it is possible to obtain 
high yields, whereas primary cell cultures have a finite lifespan (Shastry et al. 2001, 
Tieu et al. 1999). Human neuroblastoma cells, such as the SH-SY5Y line, are 
commonly used in neuroscience research to model neurological disease and exposure to 
neurotoxins, including pesticides 
1.2.1 SH-SY5Y cell line 
The SH-SY5Y human neuroblastoma cell line is a sub-clone of the parental line        
SK-N-SH originally derived from a metastatic bone tumour biopsy (Feng and Porter 
1999, Kovalevich and Langford 2013, Schneider et al. 2011, Tieu et al. 1999). 
Neuroblastoma occurs in early childhood and is a malignant tumour from cells of the 
embryonal neural crest, composed mostly of undifferentiated, neuroblast-like cells, 
which forms various tissues including the adrenal medulla and sympathetic ganglia 
(Edsjo et al. 2003, Lasorella et al. 1995, Lee et al. 2012, Pahlman et al. 1984, Sharma et 
al. 1999, Tieu et al. 1999).  
Undifferentiated neuroblastoma cells such as SH-SY5Y are used as research models in 
neuroscience, in particular to model neurotoxic processes, and are characterised as 
immature catecholaminergic sympathetic neurons (Figure 1.6) (Cheung et al. 2009, 
Krishna et al. 2014, Schneider et al. 2011, Tieu et al. 1999). The immortalised nature of 
cells such as the SH-SY5Y therefore raises the question of how closely they model the 
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original tissue type (Agholme et al. 2010). These cells lack some of the morphological 
and biochemical features of mature neurons including inhibition of cell division and 
expression of neuronal markers (Agholme et al. 2010, Nampoothiri et al. 2014). This 
raises concern as to the suitability of undifferentiated cells in toxicology studies, 
particularly if the neurotoxin being studied affects mature neurons (Agholme et al. 
2010).  
 
1.2.2 Why differentiate? 
The SH-SY5Y cell line is widely used to study the effects of neurotoxins, however there 
is on-going discussion as to which cell state, undifferentiated or differentiated, is more 
appropriate (Schneider et al. 2011). The use of undifferentiated, immortalised cell lines 
like SH-SY5Y may be necessary in certain areas of research for practical reasons. 
However, it is possible to differentiate these cells to a more mature neuronal phenotype 
that better reflects the biochemistry of a mature neuronal cell, which can help to 
determine the limits for modelling specific neurotoxic processes (Krishna et al. 2014, 
Lopez-Carballo et al. 2002, Nampoothiri et al. 2014). There are a number of chemicals 
Figure 1.6 Undifferentiated SH-SY5Y neuroblastoma cells 
cultured for three days. Sourced from (Cheung et al. 2009).  
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Figure 1.7 Chemical structure of all-trans retinoic acid. 
Obtained from (Stemgent 2012). 
that can be used to differentiate cells, with one of the most commonly used being 
retinoic acid (RA).  
1.3 Retinoic acid 
RA is a retinoid and natural morphogen commonly used to differentiate various cell 
lines in neurotoxicity research (Figure 1.7) (Dodurga et al. 2013, Lau 2007, Lopez-
Carballo et al. 2002, Miloso et al. 2004).  RA is the biologically active metabolite of 
vitamin A and plays an essential role in the nervous system during processes of 
differentiation, cell growth, organogenesis, embryonic development, germ layer and 
body axis formation, and brain and eye development (Celay et al. 2013, Kam et al. 
2012, Lau 2007, Lopez-Carballo et al. 2002, Singh et al. 2003, Tieu et al. 1999). RA 
regulates progression of the cell cycle and apoptosis in numerous malignant cell lines 
and has been shown to play a role in survival and differentiation of neurons (Miloso et 
al. 2004, Singh et al. 2003). It is also used in treatment of certain cancers including 
neuroblastoma as a therapeutic agent due to its ability to induce differentiation and 
inhibit cell proliferation (Celay et al. 2013, Lee et al. 2012, Lopez-Carballo et al. 2002).  
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The mechanism by which RA is derived from vitamin A in vivo is a two-step process: 
vitamin A (retinol) is oxidised by either alcohol dehydrogenase (ADH) or retinol 
dehydrogenase (RDH) to retinal, which is further oxidised into RA by retinaldehyde 
dehydrogenase (RALDH 1/2/3) (Duester 2008, Kam et al. 2012). As a group, the 
retinoids are able to diffuse across cell membranes due to their structure: a polyene 
hydrophobic tail attached to a cyclic 6-carbon ring (Figure 1.7) (Kam et al. 2012). This 
allows passage into cells in order to cause its biochemical effects. 
1.3.1 Mode of action 
The cellular action of RA, including its role in differentiation, is mediated by interaction 
with two nuclear receptors: retinoic acid receptors (RARs) (α, β, γ) and retinoid X 
receptors (RXRs) (α, β, γ) (Miloso et al. 2004, Tieu et al. 1999, Voigt et al. 2000). 
RARs and RXRs are ligand-regulated transcription factors that affect transcription of 
target genes (Dodurga et al. 2013, Lopez-Carballo et al. 2002). RA enters the nucleus 
where it binds RAR, and forms a heterodimer with RXR (Kam et al. 2012). The 
heterodimer subsequently binds retinoic acid response elements (RAREs) in the 
promotor region of target genes and affects gene transcription (Belbaraka 2002, Duester 
2008, Kam et al. 2012). There are 3 isoforms of RA including all-trans retinoic acid (at-
RA), 9-cis-retinoic acid and 13-cis-retinoic acid (Belbaraka 2002). The isoform of RA 
determines which receptor is activated; at-RA propagates its effects through RARs, and 
9-cis-retinoic acid through RXRs (Belbaraka 2002, Duester 2008).  
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1.4 Neuroblastoma differentiation 
The SH-SY5Y neuroblastoma cell line can be differentiated, using RA, into cells that 
are more specialised, and morphologically and biochemically similar to mature primary 
neurons (Figure 1.8) (Feng and Porter 1999, Krishna et al. 2014, Lau 2007, Sarkanen et 
al. 2007, Shastry et al. 2001). As a result of these characteristics, the cells can be used 
for in vitro neurotoxicity research (Lau 2007, Shastry et al. 2001). A wide range of RA 
concentrations, differentiation times and alternative or additional differentiation agents 
have been utilised to differentiate cells, as demonstrated in Table 1.1, indicating there is 
no clear morphological and biochemical definition of what constitutes a differentiated 
cell. A widely used concentration of RA is 10 µM, and a differentiation period of 6 days 
(Ammer and Schulz 1994).  
Cellular differentiation requires multiple cell-substrate and cell-cell interactions, and the 
cooperation of extracellular signalling molecules which encompass morphogens, growth 
factors, hormones, and trophic factors (Lopez-Carballo et al. 2002). The changes 
associated with RA-induced differentiation are regulated by gene transcription 
activation, inducing a range of morphological and biochemical changes.  
Figure 1.8 Differentiated SH-SY5Y neuroblastoma cells 
cultured with 10 µM RA for 7 days. Sourced from 
(Cheung et al. 2009). 
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Table 1.1 Differentiation conditions and criteria in SH-SY5Y neuroblastoma cells 
Source RA 
concentration 
used 
Differentiation 
length 
Differentiation 
agent used 
Differentiation criteria 
(Agholme et al. 
2010) 
10μM 10 or 21 days Combinations of 
RA, BDNF, 
neuregulin β1, 
NGF, vitamin D3 
and cholesterol 
Growth inhibition, 
neurite length and 
branching 
(Ammer and 
Schulz 1994) 
10μM 6 days RA and TPA Neurite outgrowth 
(Cheung et al. 
2009) 
10μM 7 days RA Extension of neurites 
(Constantinesc
u et al. 2007) 
10μM 14 days RA and mitotic 
inhibitors  
Neuronal markers. Cells 
elongated and extended 
neuritic processes.  
(Feng and 
Porter 1999) 
10μM 4 days RA and TPA Shrinkage of the cell 
body and extension of 
neurites, which made 
cell-cell connections 
(Korecka et al. 
2013) 
1μM 8 days RA Cells develop a mature 
DAergic-like 
neurotransmitter 
phenotype 
(Lasorella et 
al. 1995) 
5μM 6 days RA Extensive network of 
neurites 
(Lopez-
Carballo et al. 
2002) 
1μM 6 hour-4 days RA and TPA % of cells bearing long 
neurites and analysing 
the transcriptional 
activation of GAP-43 
(Miloso et al. 
2004) 
10μM 10min-5 days RA Neurites were longer 
than 50μm 
(Pahlman et al. 
1984) 
1μM 10 days RA and TPA When cells have 
processes longer than 
50μm 
(Sharma et al. 
1999) 
10μM 6 days RA Cells develop long 
neurites 
(Singh et al. 
2003) 
5μM 1-4 days RA Shrinkage of the cell 
body and extension of 
neurites 
(Tieu et al. 
1999) 
20μM 6 days RA and 
Staurosporine 
Neurites elongated and 
cell proliferation rate 
was reduced 
(Wenker et al. 
2010) 
10μM-30μM 1,4 or 7 days 
 
RA Morphological criteria 
of Lopez-Carballo  
(Yu et al. 2003) 10μM Up to 6 days RA Abundant and long 
branched neurites 
Abbreviations: BDNF: Brain-derived neurotropic factor, GAP-43: Growth associated protein 43, NGF: 
nerve growth factor, RA: retinoic acid, TPA: 12-O-tetradecanoylphorbol-13-acetate 
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1.4.1 Morphological changes 
Human SH-SY5Y neuroblastoma cells, when differentiated with RA, undergo 
morphological changes including elongation of the cell, and extensive outgrowth of 
neurites which start to form networks (Cheung et al. 2009, Clagett-Dame et al. 2006, 
Lau 2007, Xun et al. 2012). Another modification is the inhibition of cell proliferation 
which occurs as SH-SY5Y cells arrest in the G1 phase of the cell cycle by affecting the 
expression of cell cycle regulation proteins, whilst also halting DNA synthesis 
(Belbaraka 2002, Cheung et al. 2009, Constantinescu et al. 2007, Lau 2007, Schneider 
et al. 2011, Tieu et al. 1999, Tucholski et al. 2001). Morphological changes can first be 
seen 1-2 days after addition of RA, with the length and branching of neurites increasing 
during the process (Feng and Porter 1999). By contrast, undifferentiated cells maintain 
relatively short neurites (Feng and Porter 1999, Lau 2007, Pahlman et al. 1984).  
1.4.2 Biochemical changes 
RA differentiation causes not only morphological changes, but also a range of 
biochemical changes, involving regulation of genes for transcription factors, proteins, 
growth factors, enzymes, neurotransmitters, hormones, and cell surface receptors 
(Constantinescu et al. 2007).  These changes involve modification of signalling 
pathways including those related to induction of differentiation, cell cycle control, 
expression of neuronal markers, as well as survival and apoptosis regulation (Belbaraka 
2002, Lau 2007).  
1.5 Biochemical of survival and apoptosis 
The process of RA-induced differentiation in SH-SY5Y neuroblastoma cells causes a 
range of changes that are in part related to regulation of apoptosis and survival 
pathways, which modifies the biochemistry of differentiated cells. This result may 
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induce undesired effects, including not reflecting the actual toxicity of a compound 
when used in particular neurotoxicity research: including changes to Bcl-2, mitogen-
activated protein kinases (MAPKs), Phosphoinositide-3-kinase (PI3K) and tissue 
transglutaminase (TGase). 
1.5.1 Bcl-2/p53 
Bcl-2 protein is a regulator of apoptosis and may be part of the resistance mechanism 
that maintains neuronal survival (Lasorella et al. 1995). The process of RA-induced 
differentiation causes an increase in Bcl-2 levels (anti-apoptotic), whilst also causing a 
decrease in p53 and Bax levels (pro-apoptotic) (Dodurga et al. 2013, Feng and Porter 
1999, Tieu et al. 1999). The changes in levels of Bcl-2 and p53 and Bax have been 
suggested to cause a potential change in the vulnerability of the cell to toxic insult, as 
increased Bcl-2 levels suggest a decrease in apoptosis (Tieu et al. 1999). This may 
indicate that RA-induced differentiation initiates survival through activation of anti-
apoptotic pathways (Lau 2007). Therefore caution should be taken when using 
differentiated cells to represent a neuronal model, particularly when studying the effect 
of toxins on neuronal apoptosis (Dodurga et al. 2013, Lau 2007, Tieu et al. 1999).  
1.5.2 Mitogen-activated protein kinase 
1.5.2.1 ERK1/ERK2 
Mitogen-activate protein kinases (MAPKs) are a family of serine/threonine kinases 
composed of three subfamilies: extracellular signal-regulated kinases (ERKs), c-Jun N 
terminal kinases (JNKs)/stress-activated protein kinases (SAPKs) and p38 (Miloso et al. 
2004). It has been demonstrated that RA-induced differentiation stimulates 
phosphorylation of ERK1 and ERK2 MAPKs, which occurs until 96 hours post 
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PI3K PKC MEK ERK1/ERK2 
Figure 1.9 Suggested pathway for the activation of ERK1 and ERK2 MAPKs. Adapted from (Miloso et al. 
2004). 
exposure (Miloso et al. 2004). The phosphorylation of ERK1 and ERK2 was dependent 
upon protein kinase C (PKC) and phosphoinositide-3-kinase (PI3K) (Miloso et al. 
2004). In addition, it was reported that RA-induced neuritogenesis was also dependent 
on these enzymes, but was independent of ERK1 and ERK2 (Miloso et al. 2004). 
Effects on cell survival were also examined and suggested that in both undifferentiated 
and differentiated cells, survival is dependent upon ERK1, ERK2 and PKC (Cheung et 
al. 2009, Lau 2007, Miloso et al. 2004).  
As it has been shown that PI3K is required for activation of certain PKC isoforms, a 
novel cascade has been suggested by Miloso et al. (2004) (Figure 1.9) in response to 
RA where PKC phosphorylates and activates MAPK/ERK kinase (MEK, a 
threonine/tyrosine kinase) causing phosphorylation and activation of ERK1 and ERK2 
MAPKs.  
Activated ERK1 and ERK2 have the ability to phosphorylate cytoplasmic proteins 
which include signal transduction and cytoskeletal proteins, and may translocate to the 
nucleus where the enzymes can phosphorylate various transcription factors, thereby 
regulating expression of associated genes (Miloso et al. 2004).  
In comparison of other studies, Singh et al. (2003) also suggested that active ERK is not 
required for RA-induced neuritogenesis to occur, although a different MEK inhibitor 
was utilised which Miloso et al. (2004) found only gave a time-dependent reversible 
inhibition. In addition, Miloso et al. (2004) focused on 24-hour post RA exposure, only 
including early changes which are not representative of the complex and longer process 
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of differentiation. Therefore while ERK phosphorylation may not be required in the 
early stages, it may in the later stages (Miloso et al. 2004).  
1.5.3 PI3K/Akt 
Phosphoinositide 3-kinases (PI3Ks) are a lipid-kinase family that phosphorylate inositol 
ring 3’-OH groups in inositol phospholipids (Vara et al. 2004). Lopez-Carballo et al. 
(2002) demonstrated that RA-induced differentiation activates the PI3K/Akt pathway, 
resulting in increased PI3K activity and phosphorylation of Akt. Akt (also known as 
protein kinase B) is a primary target of PI3K and is crucial in survival, cell cycle 
progression and growth (Cheung et al. 2009, Joshi et al. 2006, Korecka et al. 2013, Lau 
2007, Pan et al. 2005, Vara et al. 2004). Akt is also important in cell death regulation as 
it has the ability to phosphorylate and inactivate the pro-apoptotic proteins Bad and 
Procaspase 9, and activate anti-apoptotic genes (Vara et al. 2004). Through use of the 
PI3K inhibitor LY294002, the effect on differentiation indicated that activation of the 
PI3K/Akt pathway by RA is crucial for transcription of genes necessary for neuronal 
survival and differentiation (Lopez-Carballo et al. 2002, Pan et al. 2005, Wenker et al. 
2010).  
1.5.4  ID transcription factors 
Basic helix-loop-helix transcription factors are a gene family that regulate lineage 
commitment and cellular differentiation (Lopez-Carballo et al. 2002). RA-induced 
differentiation caused a decrease in expression of the differentiation-inhibiting basic 
helix-loop-helix transcription factors ID1, ID2 and ID3 (Cheung et al. 2009, Lopez-
Carballo et al. 2002). It was demonstrated that RA causes a decrease in expression of 
the ID transcription factors through newly synthesised proteins as well as PI3K activity 
(Lau 2007, Lopez-Carballo et al. 2002).  
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The differentiation process caused further changes to other basic-helix-loop-helix 
transcription factors including increased expression of NEUROD1 and NEUROD6, 
both differentiation-promoting transcription factors (Lopez-Carballo et al. 2002). The 
increased expression of differentiating-promoting genes are part of the process of 
initiating differentiation and caused transcriptional activation of neuron specific genes, 
including growth associated protein 43 (GAP-43) whilst also activating proteins in post-
mitotic neuron growth cones (Lopez-Carballo et al. 2002).  
1.5.5 PI3K/Rho GTPases 
PI3K is also involved in activation of Rho GTPases, including RhoA, Rac1 and Cdc42. 
These are necessary for the regulation of signal transduction pathways in the process of 
differentiation, and they also play a part in cytoskeletal rearrangement and cell cycle 
control (Pan et al. 2005). RA is responsible for PI3K mediated activation of Rac1 and 
its downstream target PAK1, both of which stimulate survival, outgrowth of neurites, 
MAPK activation and neuronal marker expression (Clagett-Dame et al. 2006, Korecka 
et al. 2013, Lau 2007, Pan et al. 2005). Inhibitors of PI3K or Rac1 block this 
expression, indicating their activation is important for RA-induced differentiation (Pan 
et al. 2005).  
1.5.6 Tissue transglutaminase 
Another biochemical change induced by RA-induced differentiation is in relation to 
tissue transglutaminase (TGase). TGase is a type of multifunctional G protein operating 
through the binding and hydrolysis of guanosine triphosphate (GTP), whilst playing a 
role in signal transduction pathways, and exhibiting transglutaminase (transamidation) 
activity (Joshi et al. 2006, Singh et al. 2001, Singh et al. 2003, Tucholski et al. 2001).  
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RA differentiation induces the expression and activation of TGase, including its 
transamidation function, which is necessary for neuronal differentiation to occur in SH-
SY5Y cells (Lee et al. 2012, Singh et al. 2003, Tucholski et al. 2001). TGase activation 
may also play a part in regulation of apoptosis and have an important role in outgrowth 
of neurites (Tucholski et al. 2001). Further, TGase also activates ERK1/ERK2, JNK1 
and p38γ MAP kinases, and increases the expression of GAP-43 and NF-B neuronal 
markers (Singh et al. 2003, Tucholski et al. 2001). GAP-43, a neuron-specific protein, 
is present in growth cones required for guiding the outgrowth of neurites, whilst 
neurofilament (NF) proteins make up major fibrillary elements of the neurite 
cytoskeleton, both of these neuronal markers are necessary for differentiation (Singh et 
al. 2003).  
RhoA is a member of the Rho family of small G proteins, which also includes Rac1 and 
Cdc42 (Pan et al. 2005, Singh et al. 2003). The increase in transglutaminase activity 
allows transamidation of RhoA (Singh et al. 2003). Activated RhoA is required for 
cytoskeletal rearrangements and the activation of ERK1/ERK2 and p38γ MAP kinases 
(Singh et al. 2003). Activated RhoA also binds and activates ROCK-2 (Rho-associated 
protein kinase-2) (Figure 1.10), a downstream effector of RhoA, leading to increased 
stress fibre and focal adhesion complex formation (Singh et al. 2001, Singh et al. 2003).  
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Figure 1.10 Targets of activated tissue transglutaminase (TGase) and 
RhoA. Sourced from (Singh et al. 2003). 
 
1.5.7 Matrix metalloproteinase 
RA-induced differentiation, through action of TGase and RARs, causes migration and 
invasion (Joshi et al. 2006, Lee et al. 2012). Matrix metalloproteinase-9 (MMP-9) and 
MMP-2 are involved in cancer cell invasion and are a target of RA differentiation-
induced NF-κB (Lee et al. 2012). Induction of MMPs has been correlated with the 
aggressiveness of neuroblastoma (Lee et al. 2012). It has been proposed that RA-
induced TGase could activate NF-κB and therefore mediate MMP-9 and MMP-2 
activation and invasion (Lee et al. 2012).  
1.5.8 Neutral ceramidase 
Ceramidase (CDase) is an important enzyme that controls intracellular ceramide 
breakdown, hydrolysing ceramide into a fatty acid and sphingosine which can then 
produce sphingosine-1-phosphate (S1P) (Tanaka et al. 2012). Ceramide can also be 
synthesised to sphingomyelin and glycosphingolipid, or phosphorylated to ceramide-1-
phosphate (C1P) by ceramide kinase (CERK) (Murakami et al. 2010). There are three 
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types of CDase: neutral CDase, lysosomal acid CDase and alkaline CDase (Tanaka et 
al. 2012). Neutral ceramidase (NCDase) is crucial for regulating ceramide levels, and is 
involved in sphingolipid metabolism, cellular differentiation and intracellular signalling 
in relation to apoptosis (Murakami et al. 2010, Tanaka et al. 2012). RA-induced 
differentiation in SH-SY5Y neuroblastoma cells caused an increased in production of 
ceramide and a down regulation of NCDase enzymatic activity (Tanaka et al. 2012). 
GATA-2 is a transcription factor that helps to regulate levels of NCDase, and RA-
induced differentiation caused a decrease in GATA-2 levels (Tanaka et al. 2012). This 
resulted in a down regulation of NCDase and subsequent intracellular ceramide 
accumulation (Tanaka et al. 2012). Down regulation of NCDase is therefore crucial for 
ceramide modulation in the process of RA-induced differentiation. 
Another enzyme regulated by RA exposure is CERK, as differentiation caused a 
decrease in CERK levels which were concentration and time-dependent (Murakami et 
al. 2010). CERK has been demonstrated to have an inhibitory effect on differentiation 
and cell proliferation (Murakami et al. 2010). The mechanism of the RA-induced 
decrease was through inhibition of 5’ promoter transcriptional activity of CERK due to 
the presence of tandem RAREs (Murakami et al. 2010).  
1.6 Initiation of differentiation 
RA-induced differentiation causes a range of biochemical changes in SH-SY5Y 
neuroblastoma cells that are involved in initiating differentiation, or occur as a result of 
the process. This causes modifications to the biochemistry of differentiated cells that 
may induce undesired effects when used for particular neurotoxicity research. These 
include changes to mitogen-activated protein kinases (MAPKs), G proteins and 
functioning of the mitochondria: 
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1.6.1 Neuronal markers 
During the process of RA-induced differentiation, SH-SY5Y cells express certain 
factors which can be identified as neuronal markers (Mattsson 1989, Xun et al. 2012). 
The differentiation process can be characterised by investigating the changes in 
expression of these markers as indicators of a mature, differentiated phenotype (Lau 
2007, Pahlman et al. 1984). 
These include neuron-specific enolase (NSE), synaptophysin, NeuN, GAP-43, NF 
proteins, microtubule-associated protein 2 (MAP-2), β-III tubulin, synaptic associated 
protein 97 (SAP-97), secretogranin II, synaptic vesicle protein 2 (SV2) and the anti-
apoptotic factor Bcl-2, all of which show increases after RA-induced differentiation 
(Belbaraka 2002, Cheung et al. 2009, Mattsson 1989, Schneider et al. 2011, Singh et al. 
2003, Tanaka et al. 2012, Tieu et al. 1999, Wenker et al. 2010). These markers are 
indicators of neuronal secretory, synaptic, and growth cone activity, maturation, 
cytoskeletal rearrangements and neurite outgrowth (Agholme et al. 2010, 
Constantinescu et al. 2007, Lau 2007, Sarkanen et al. 2007).  
1.6.2 Mitogen-activated protein kinase 
1.6.2.1 JNK 
c-Jun N terminal kinases (JNKs) are also part of the MAPK family and encoded by 3 
genes; JNK1, JNK2 and JNK3 (Davis 2000). Singh et al. (2003) and Yu et al. (2003) 
demonstrate that JNK1 plays a crucial role in initiation of RA-induced differentiation 
and neurite outgrowth in SH-SY5Y neuroblastoma cells. Application of RA induced 
two periods of JNK1 activation: firstly within 10 minutes, and secondly, approximately 
24 hours post treatment (Yu et al. 2003). The latter of which accompanied significant 
neurite outgrowth (Yu et al. 2003). During early activation, phosphorylated JNK was 
21 
 
localised in the nucleus suggesting JNK1 may be important in induction of genes 
required for differentiation (Yu et al. 2003). During the second activation JNK1 was 
localised in growing neurites  (Yu et al. 2003). 
Singh et al. (2003) also demonstrated that RA increased activation of JNK1, and agreed 
that JNK activation induced the expression of genes necessary for neuronal 
differentiation. But unlike Yu et al. (2003) who indicated that JNK1 plays a crucial role 
in outgrowth of neurites, Singh et al. (2003) found that when a JNK inhibitor was 
applied RA-induced neurite outgrowth was not affected. Differences may be accounted 
for by experimental variations including the different concentrations of RA used, and 
the fact that the JNK inhibitor was applied before RA exposure. It should also be noted 
that Yu et al. (2003) came to a conclusion based on a causative effect of JNK1 
activation and neurite outgrowth.  
1.6.3 NF-κB 
The NF-κB transcription factors are part of a family consisting of at least 5 members: 
NF-κB1 (p50), NF-κB2 (p52), RelA (p65), RelB and c-Rel, which bind to a specific 
DNA consensus motif upon activation as either homo- or heterodimers (Feng and Porter 
1999). These various dimers are usually located in the cytoplasm and masked by 
inhibitors including I-κBα, I-κBβ and I-κBγ, which impede the nuclear localisation 
signal of NF-κB (Feng and Porter 1999). Phosphorylation of these inhibitors causes 
their release from NF-κB, uninhibiting the nuclear localisation signal, allowing 
subsequent NF-κB nuclear localisation and activation (Feng and Porter 1999, Lee et al. 
2012). The process of RA-induced differentiation changes the expression, activation 
and cellular localisation of the NF-κB/Rel group of transcription factors (Feng and 
Porter 1999, Lee et al. 2012). It has been demonstrated that by inhibiting activation of 
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NF-κB, differentiation is suppressed as seen through morphological and biochemical 
factors. This indicates that NF-κB/Rel proteins are necessary for neuronal 
differentiation (Feng and Porter 1999). 
1.6.4 G proteins 
Another biochemical change induced by RA-induced differentiation is in relation to G 
proteins. G protein-coupled receptors (GPCRs) are the largest family of membrane-
bound proteins and activate cellular responses through G protein mediated signal 
transduction pathways (Kobilka 2007, Tuteja 2009). Two classes of G proteins exist; 
the monomeric and the heterotrimeric G proteins, consisting of α, β and γ subunits 
(Purves 2001, Tuteja 2009).  
RA-induced differentiation causes changes in abundance of particular inhibitory and 
stimulatory G protein subunits due to regulation of the associated receptor, modifying 
activity of downstream effector molecules (Ammer and Schulz 1994, Baumgartner 
1993). Stimulatory and inhibitory G proteins are involved in mediating the signal from 
PGE1 (prostaglandin E1) and μ-opioid receptors to the subsequent intracellular effector 
systems (Ammer and Schulz 1994). Ammer and Schulz (1994) demonstrated an up-
regulation of μ-opioid receptors in response to 10 µM RA which coordinated with an 
increase in functional Giα1 and Giα2 inhibitory G proteins, as both are coupled to μ-
opioid receptors in SH-SY5Y cells. Differentiation subsequently caused an increase in 
μ-receptor mediated adenylyl cyclase inhibition (Baumgartner 1993). Differentiation 
also caused upregulation of PGE1 receptors which have a reciprocal relationship with 
Gsα, the G protein subunit that activates adenylyl cyclase (Ammer and Schulz 1994, 
Baumgartner 1993). However, there was a decrease in the amount of Gsα, coupled to a 
decrease in stimulatory activity of the G protein (Ammer and Schulz 1994). Although, 
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this had no effect on intrinsic or receptor-independent-activated adenylyl cyclase, 
potentially indicating that the amount of Gsα was over the functional capacity of 
adenylyl cyclase (Ammer and Schulz 1994).  
1.6.5 CDK-5 
Cyclin-dependent kinase 5 (CDK-5) is mostly expressed in neuronal cells; while its 
kinase activity is found only in post-mitotic cells (Sharma et al. 1999).  CDK-5 is reliant 
on associating with brain-specific activators p67, p35/p25 and p39 (Sharma et al. 1999). 
The process of RA-induced differentiation caused an increase in CDK-5/p35 activity 
(Lau 2007). Antisense oligonucleotides designed to inhibit CDK-5 expression were 
used to determine the role CDK-5 plays in phosphorylation of NF proteins and neurite 
extension (Sharma et al. 1999). RA exposure was found to increase the phosphorylation 
of high molecular mass (NF-H) and medium molecular mass (NF-M) neurofilament 
proteins, which correlated with an increase in neurite outgrowth (Sharma et al. 1999).  
This occurs through phosphorylation of serine/threonine sites in lys-ser-pro-X-lys 
(KSPXK)-type motifs contained in the C-terminal tail domain of NF proteins (Sharma 
et al. 1999). Therefore the data indicates that CDK-5 catalyses the phosphorylation of 
NF-H and NF-M, and is therefore important for inducing neurite outgrowth in RA 
differentiated SH-SY5Y neuroblastoma cells (Sharma et al. 1999). 
1.6.6 Mitochondria and oxygen consumption 
Further biochemical changes due to differentiation were found in relation to the 
mitochondria. In eukaryotic cells, the mitochondria are responsible for the production of 
metabolic energy and are an important effector in RA-induced differentiation of SH-
SY5Y cells (Schneider et al. 2011). Induction of a neuronal phenotype alters cellular 
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metabolism and causes a range of mitochondrial changes including response to 
oxidative stress and bioenergetic functions (Korecka et al. 2013, Schneider et al. 2011, 
Xun et al. 2012).  
It is important for neuronal cells to sustain sufficient bioenergetic capacity to meet 
energy demand, which includes spare capacity that may be important in situations of 
cellular stress (Schneider et al. 2011, Xun et al. 2012). It has been found that 
undifferentiated cells do not possess significant spare bioenergetic capacity; whilst 
differentiated cells induced a significant increase in maximum respiratory capacity, 
suggesting spare capacity (Schneider et al. 2011, Xun et al. 2012). This suggests that, 
when under conditions of stress such as toxicity, the cells may have access to a higher 
bioenergetic capacity and can potentially handle stress more efficiently than 
undifferentiated cells (Schneider et al. 2011). Differentiated cells also saw an increase 
in mitochondrial antioxidant manganese superoxide dismutase (MnSOD), which has 
been suggested to play a crucial role in decreasing effects of oxidative stress (Schneider 
et al. 2011). 
Schneider et al. (2011) found there was no significant difference in adenosine 
triphosphate (ATP)-linked basal O2 consumption rate (OCR) between undifferentiated 
and differentiated cells, which suggests there is no increased demand for ATP in RA-
induced differentiated cells. To meet these respective energy requirements, 
undifferentiated cells appear to depend more on glycolysis, whilst differentiated cells 
show dependence on oxidative phosphorylation, which may indicate reliance on 
different energy sources (Schneider et al. 2011, Xun et al. 2012). 
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1.7 Retinoic acid-induced neuroprotection 
RA-induced differentiation of SH-SY5Y is a useful tool that can produce cells that are 
characteristic of mature neurons, and can be utilised in neuroscience to study the effect 
of particular neurotoxins, including pesticides. It is important to understand the potential 
effect of RA differentiation on the toxicity of pesticides and their metabolites, such as 
malathion and malaoxon (Johnson et al. 2012). Neuroprotection involves maintaining 
the structure and function of the nervous system, whilst limiting any dysfunction or 
death resulting from insult. Changes in cellular biochemistry associated with RA-
induced differentiation, including alterations to neuroprotection and regulation of 
apoptosis and survival may affect the susceptibility of these cells against toxic insult of 
certain neurotoxins. Using differentiated cells may therefore potentially undermine the 
validity of neurotoxicity research. 
Exposure of different neurotoxins to RA-differentiated cells has variable effects on 
cellular biochemistry (Lau 2007). For example, chemo-resistance has been reported in 
RA-induced differentiated SH-SY5Y cells, where the toxic effect of adriamycin (Adr) 
and cisplatin were suppressed (Lasorella et al. 1995, Tieu et al. 1999). This indicates 
that differentiation caused a decrease in apoptosis and increased resistance to cytotoxic 
threats, which in part may be due to an increase in Bcl-2 expression (Belbaraka 2002, 
Lasorella et al. 1995). Changes in the regulation of apoptosis are related to cellular 
changes that occur due to RA inducing a neuronal phenotype, affecting the vulnerability 
of cells to insult (Lasorella et al. 1995, Tieu et al. 1999).  
The parkinsonian mimetic toxins 6-hydroxydopamine (6-OHDA) and 1-methyl-4-
phenylpyridinium (MPP
+
), which are used to simulate Parkinson’s disease, also affected 
SH-SY5Y cellular biochemistry as differentiated cells were more resistant to cell death 
than undifferentiated cells (Cheung et al. 2009, Lau 2007). One possible reason that is 
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suggested for this neuroprotection may be the activation of the Akt pathway (Cheung et 
al. 2009, Lau 2007). Caution should therefore be taken when using RA-differentiated 
cells as a model for neuronal cells to study toxic insult, as RA may change the 
susceptibility and survival of neuroblastoma cells (Cheung et al. 2009, Lau 2007, Tieu 
et al. 1999).  
More research is required to study the nature of these neurotoxic effects on both cell 
states in relation to neuroprotection, susceptibility and survival which is one focus of 
this study. A technique that could be used to help analyse some of these biochemical 
changes associated with the RA-induced differentiation of neurons is GC-MS-based 
metabolomic analysis, which will be utilised in this study. This may help determine 
which cell state, undifferentiated or differentiated, is more appropriate for neurotoxicity 
research and for general neuroscience research. 
1.8 Metabolomics 
Metabolomics is an emerging field involving the identification and analysis of low 
molecular weight metabolites within a biological sample, typically up to 1.5-2.0 kDa in 
mass (Dettmer et al. 2007, Idle and Gonzalez 2007, Johnson et al. 2012). It utilises a 
process that involves sampling, sample preparation, instrumental analysis, and 
processing and interpretation of the data (Dunn and Ellis 2005). Due to the speed of 
metabolic processes, rapid inhibition of samples via quenching and harvesting is 
required which produces a snapshot of the metabolome at a particular time point (Dunn 
and Ellis 2005). Sample preparation involves extracting the metabolites from the 
harvested cellular material for analysis, and chemical derivatisation which enables 
analysis of non-volatile metabolites as well as volatile compounds (Villas-Bôas et al. 
2005). The technique used in this study is silylation derivatisation which is one of the 
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most widely used derivatisation techniques for gas chromatography-mass spectrometry 
(GC-MS) metabolomic analysis (Villas-Bôas et al. 2005). The level of instrumental and 
data analysis can vary depending on the research questions. It may involve a targeted 
analysis that focuses on identification and quantification of pre-defined metabolites, or 
untargeted metabolite profiling as utilised by this study that involves analysis of all 
detectable metabolites, that is often not quantitative (Villas-Bôas et al. 2005). 
Processing of the data generates a mass spectrum for each feature detected within each 
sample that can be used for identification or quantification of metabolites, followed by 
statistical analysis required for biological interpretation.  
This “omics” field is gaining traction in comparison to the more well-known areas of 
genomics, transcriptomics and proteomics, and is considered to be the closest to the 
phenotype of a biological system (Figure 1.11) (Dettmer et al. 2007, Idle and Gonzalez 
2007, Johnson et al. 2012). The metabolome encompasses all metabolites in a biological 
sample including metabolic intermediates, hormones and secondary metabolites etc. and 
consists of a diverse range of compounds which belong to a number of different classes 
e.g. lipids, amino acids, carbohydrates and organic acids (Dettmer et al. 2007, Dunn and 
Ellis 2005, Villas-Bôas et al. 2005). The genome and transcriptome consist of different 
arrangements of only 4 nucleotide bases, and the proteome of 20 different amino acids, 
and these upstream changes do not give information that is sufficiently definitive to 
outline downstream biochemical functions (Dunn and Ellis 2005, Fiehn 2002).  
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Metabolites are the intermediates and end products of cellular processes and are 
therefore used to determine changes to metabolic pathways, as well as answering an 
increasing number of biological questions in relation to how the phenotype changes due 
to disease, environmental or genetic influences (Dettmer et al. 2007, Johnson and 
Gonzalez 2012, Johnson et al. 2012). As understanding the phenotype can be illustrated 
at the metabolic level (Fiehn 2002). In order to answer these questions, metabolomics 
can utilise mass spectrometry coupled to a separation technique, one of the more 
commonly used being GC-MS.  
1.8.1 GC-MS 
There are many analytical techniques that can be used for metabolomic analysis, 
although there is no single approach that can encompass the entire metabolite range 
(Dettmer et al. 2007). Mass spectrometry is an analytical technique that can detect any 
DNA-Genomics 
RNA-Transcriptomics 
Protein-Proteomics 
Metabolites-Metabolomics 
Phenotype 
Environmental influence 
What can happen 
What appears to be happening 
What makes it happen 
What is actually happening 
Figure 1.11 ‘Omics’ cascade. Demonstrating that metabolomics studies the products of the 
cascade and the metabolome is closest to the phenotype. Adapted from Dettmer, Aronov 
and Hammock (2007). 
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molecule that can be ionised in a given sample whilst also identifying composition and 
structural information (Watson and Sparkman 2008). GC-MS is a core technique for 
metabolomic analyses due to its ability to produce qualitative and quantitative data in a 
rapid, sensitive and selective fashion, whilst being able to resolve complex samples 
(Dunn and Ellis 2005, Tsugawa et al. 2011).  
Separation via GC is the first part of the process: the unknown sample is injected into 
the GC and immediately vaporised (Figure 1.12). Compounds are subsequently 
separated in a capillary column due to variation in their boiling point (Watson and 
Sparkman 2008). This causes different interactions of the compound with the stationary 
and mobile phases causing separation and elution of the compounds at different times 
(Watson and Sparkman 2008). Compounds are then introduced into the mass 
spectrometer which is composed of three sections; the ion source, mass analyser and ion 
detector. A common ion source, and the one used for this research, is electron ionisation 
(EI) (Watson and Sparkman 2008). EI operates via colliding the eluting compounds 
with a beam of high energy electrons, resulting in compound ionisation and 
fragmentation (Watson and Sparkman 2008). For the mass analyser component, a single 
quadrupole was used in this study. It separates ions based on a selected mass-to-charge 
ratio (m/z) and consists of four metal rods with opposite pairs having either direct 
current or radio frequency electric fields (Watson and Sparkman 2008). The ions are 
accelerated toward the detector, and ions that have a different m/z to the one selected 
will either collide with or escape the rods (Watson and Sparkman 2008). An electron 
multiplier detects the ions emerging from the mass analyser by hitting the detector 
surface causing secondary electrons to be emitted which are further amplified, and the 
abundance of ions at a particular m/z are collected (Watson and Sparkman 2008).  
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Analysis of the GC-MS data requires the use of compound libraries and databases that 
can be utilised to identify metabolites through mass spectra, as compounds have unique 
and reproducible fragmentation patterns and retention times (Dettmer et al. 2007, 
Garcia and Barbas 2011, Lenz and Wilson 2007, Tsugawa et al. 2011, Watson and 
Sparkman 2008). Identified metabolites can be analysed for changes in expression 
across different sample groups and mapped to biochemical pathways, from which 
biological significance can be determined. 
Advantages of GC-MS include high selectivity, sensitivity and chromatographic 
resolution, reproducible retention times and fragmentation patterns, the ability to handle 
a larger number of samples, and the presence of comprehensive, publicly available 
libraries and databases that provide the ability to identify metabolites (Dettmer et al. 
2007, Garcia and Barbas 2011, Johnson and Gonzalez 2012, Lenz and Wilson 2007, 
Tsugawa et al. 2011). These advantages indicate that GC-MS is an excellent technique 
for metabolomic analyses (Dettmer et al. 2007, Lenz and Wilson 2007).  
 
 
Figure 1.12 Diagram of a typical gas chromatography-mass spectrometry work flow. Obtained 
from (Scientific 2010). 
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Some disadvantages of GC-MS include that it is not possible to analyse all metabolites 
in a biological sample on one instrument, sample preparation can potentially cause some 
metabolite loss, and also analytes have to be thermally stable and volatile or have the 
ability to be made thermally stable, which requires a derivatisation step for non-volatile 
analytes (Dettmer et al. 2007, Garcia and Barbas 2011, Johnson and Gonzalez 2012, 
Lenz and Wilson 2007). Derivatisation chemically modifies a compound to greatly 
improve the chromatographic stage of analysis, increasing reproducibility and 
efficiency (Sellers 2007). Without the derivatisation process there would be problems 
with non-reproducible peak area, height and shape, as well as overlapping peaks and 
compounds co-eluting (Sellers 2007). 
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1.10 Hypothesis and aims 
This overview has highlighted the changes induced by RA differentiation on SH-SY5Y 
neuroblastoma cells found in the literature to date. These studies have focused mainly 
on the upstream changes associated with gene expression and enzyme activity. Little 
work exists on the changes in downstream biochemistry, or the metabolome, and to the 
best of the author’s knowledge, analysis of RA-induced differentiation of SH-SY5Y 
neuroblastoma cells using an untargeted metabolomic approach has not yet been 
undertaken. For this reason we proposed to utilise metabolomic analysis to determine 
the small molecule biochemical changes associated with RA-induced differentiation. 
The data obtained will be reflective of modifications in the phenotype, thereby 
demonstrating what is ‘actually happening’ in the biological system. This may help 
determine whether undifferentiated or differentiated SH-SY5Y neuroblastoma cells are 
more appropriate for toxicology as well as for neuroscience research more generally. 
We hypothesise that there will be changes to the small molecule biochemistry 
associated with differentiating SH-SY5Y cells with RA, which can be measured using 
GC-MS, and that these changes will alter the response of the SH-SY5Y cells to 
malaoxon, the toxic metabolite product of the OP pesticide malathion.  
The specific aims of this study were to: 
1. Optimise the conditions required to differentiate SH-SY5Y human 
neuroblastoma cells using retinoic acid. 
2. Establish baseline metabolite profiles for undifferentiated and retinoic acid-
differentiated SH-SY5Y neuroblastoma cells using GC-MS.  
3. Identify the changes in biochemical pathways due to retinoic acid differentiation 
in SH-SY5Y cells.  
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4. Determine the biochemical response (as measured by GC-MS) to malaoxon in 
undifferentiated and retinoic acid-differentiated SH-SY5Y neuroblastoma cells.  
5. Use the data obtained to assess whether differentiated or undifferentiated cells 
may be more appropriate for use in future neuronal toxicology research.  
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2. Materials and methods 
2.1 Chemicals 
All chemicals used were of the highest purity available. Retinoic acid (RA) (Sigma-
Aldrich, NSW Australia) was solubilised in analytical grade ethanol (Ajax Finechem, 
NSW Australia) to a concentration of 1 mg/mL. 1 mL aliquots of the stock solution 
were stored at -20ºC. Malaxon (Sigma-Aldrich) was solubilised in liquid 
chromatography-mass spectrometry (LC-MS) grade methanol (Merck, Darmstadt 
Germany) to a concentration of 200 mg/mL and stored at -80°C. Trypan blue solution 
was part of the EVE automatic cell counting kit (NanoEntek, CA USA). Phosphate 
buffered saline (PBS), 
13
C6-sorbitol, n-methyl-n-(trimethylsilyl)trifluroacetamide 
(MSTFA), and methoxyamine hydrochloride derivatisation agents, and all cell culture 
reagents were purchased from Sigma Aldrich. Ethanol (Ajax FineChem) was used for 
decontamination of cell culture equipment and diluted to 70% with w/v HPLC-grade 
water (Fisher Scientific). Pyridine was used as a derivatisation solvent (APS chemicals, 
NSW Australia). n-alkanes (C10, C12, C15, C19, C22, C28, C32, C36) (Chem Service, West 
Chester PA) were solubilised in n-hexane (95%) (Ajax Finechem), to concentrations of 
0.625 mg/mL for C10 to C28 and 1.25 mg/mL for C32 and C36. 
2.1.2 Cell culture 
Human neuroblastoma SH-SY5Y cells, purchased through Sigma-Aldrich from The 
European Collection of Cell Cultures, were grown in 75 cm
2
 cell culture flasks and 
incubated at all times (unless otherwise stated) at 37°C, 5% CO2 in a humidified 
environment using the Thermo Scientific Heraeus BB15 Function Line CO2 incubator 
(Scoresby, Australia). Cells were grown in a 1:1 medium of Dulbecco’s Modified Eagle 
Medium (DMEM) and Ham’s nutrient mixture, supplemented with 1% (w/v)  
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L-glutamine, 1% (w/v) penicillin and streptomycin, and 5% (v/v) foetal calf serum 
(FCS, heat inactivated at 56 °C for 2 hours). Passages from 29 to 50 were used for this 
study. Cell culture work was undertaken in aseptic conditions using ethanol- and UV-
treated surfaces and equipment. Prior to experimentation or passaging, cultures were 
grown to 80-90% confluence. To dislodge cells from the bottom of the flask for 
passaging, the cell medium was removed and discarded, and 2 mL of 10x trypsin 
(Sigma Aldrich) diluted to 1x in 1:1 DMEM:Ham’s was added. Cells were trypsinised 
for 2 minutes under incubation at    37 °C and 5% CO2. This process was terminated by 
adding 8 mL of 1:1 DMEM and Ham’s nutrient media. Cells were resuspended and 
aliquoted into fresh flasks made up to 10 mL with 1:1 DMEM and Ham’s.  
Cells were checked regularly using an Olympus IMT-2 inverted research microscope 
(Tokyo, Japan). Cell photographs were taken to compare growth and morphological 
changes between control and treated cells, using Moticam 2300 camera (Motic 
instruments Inc., Hong Kong), and Motic Images Plus Software (v2.0) in combination 
with Olympus CKX41 microscope (Tokyo, Japan).  
2.1.3 Cell counts 
Cells were counted to determine the cell count/mL, as well for use as a correction factor 
for metabolite analysis. Cells were counted using the EVE automated cell counter 
(NanoEntek), using the Trypan blue exclusion method. All medium from the well was 
discarded and 250 µL and 500 µL of 1 x trypsin was added to 24 and 6-well plates 
respectively. Following trypsinisation for 2 minutes under incubation at 37°C and 5% 
CO2, an equal volume of 1:1 DMEM:Ham’s was added. The cells were resuspended and 
an aliquot of 10 µL was added to a 96-well plate and mixed with 10 µL of 0.4% v/v 
Trypan blue solution. 10 µL of this cell/Trypan blue solution was added to an EVE 
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counter slide and the concentration (cells/mL) was calculated. Viable cells will not take 
up the dye and appear white. Non-viable cells will take up the Trypan blue dye due to a 
porous membrane, and therefore will look dark blue. The automatic cell counter 
determines viable, non-viable and total cells/mL, plus the viability (%).  
2.2 Optimisation of differentiation 
2.2.1 Seeding density 
Confluent SH-SY5Y cells at passage 39 were seeded at three densities as a ratio of the 
proportion of the 10 mL flask volume used to seed one plate; 1:2, 1:4 and 1:6, in 24-
well plates in 1:1 DMEM:Hams media and incubated for 48 hours to settle and adhere 
to the wells (see workflow in Figure 2.1). Control and treatment plates for exposure 
times of 24, 48, 72, 96, 120 and 144 hours, were set up with 4 wells for each density to 
be counted and photographed at time of treatment. One initial time 0 plate was also used 
to indicate the initial cell count/mL. Retinoic acid (RA) solution was freshly prepared 
from the stock aliquots and diluted with 100% ethanol. RA was added to the test wells 
to a final concentration of 10 µM. The same volume of ethanol solution, 10 µL, was 
added to the control wells as a vehicle control. For all plates, the final concentration of 
ethanol in the medium was ≤1% total volume. The concentration of RA was chosen due 
to a reasonable consensus from the literature (see Table 1.1). Following incubation for 
the respective exposure times, 4 wells from each plate were photographed and counted 
(as described in 2.1.3). During the course of experimentation the medium was not 
changed.   
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Cell Culture 
Treatment 
24-well plates seeded from 
flasks at 1:2, 1:4, 1:6 
seeding densities 
Left to settle for 48 hours 
10 µM retinoic acid was 
added to treatment plates 
Incubated for 0, 24, 48, 72, 
96, 120 and 144 hours 
Cells photographed and counted 
EVE automatic cell counter 
Figure 2.1. Simplified workflow for the seeding density optimisation 
experiment (as detailed in section 2.2.1). 
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2.2.2 Retinoic acid concentration 
Confluent SH-SY5Y cells at passage 41 were seeded 1:4 on 24-well plates in 1:1 
DMEM:Hams media and incubated for 48 hours to settle and adhere to the wells (See 
workflow in Figure 2.2). Control and treatment plates for exposure times of 24, 48, 72, 
96, 120 and 144 hours were set up with 4 wells to be counted and photographed at each 
time point. One initial time 0 plate was also used to indicate the initial cell count/mL. 
RA solution was freshly prepared from the stock aliquots, diluted with 100% ethanol to 
4 different final concentrations of RA. The RA was added to the test wells to a final 
concentration of 1, 5, 10 or 20µM. These concentrations of RA were chosen to reflect 
the range that has been used in the literature (see Table 1.1). The same volume of 
ethanol solution, 10 µL, was added to the control wells as a vehicle control. For all 
plates, the final concentration of ethanol in the medium was ≤1% total volume. 
Following incubation for the respective exposure times, 4 wells from each plate were 
photographed and counted (as described in 2.1.3). During the course of experimentation 
the medium was not changed.   
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Cell Culture 
Treatment 
24-well plates seeded from 
flasks at a 1:4 seeding 
density 
Left to settle for 48 hours 
1, 5, 10 and 20 µM 
concentrations of retinoic 
acid was added to 
treatment plates 
Incubated for 0, 24, 48, 72, 
96, 120 and 144 hours 
Cells photographed and counted 
EVE automatic cell counter 
Figure 2.2. Simplified workflow for determining the optimum retinoic acid 
concentration (as detailed in section 2.2.2). 
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2.3 Analysis of differentiation in 6- and 24-well plates 
Confluent SH-SY5Y cells at passage 29 were seeded 1:4 in 6 and 24-well plates in 1:1 
DMEM:Hams media and incubated for 48 hours to settle and adhere to the wells (See 
workflow in Figure 2.3). Control and treatment plates, containing harvest wells and a 
count well for exposure times of 24, 48, 72, 96, 120 and 144 hours were set up. For each 
well included on a 6-well plate, 4 wells were utilised on a 24-well plate. RA solution 
was freshly prepared from stock aliquots, and diluted with 100% ethanol. RA was added 
to the treatment wells for a final concentration of 10 µM. The same volume of ethanol 
solution, 10 µL, was added to the control wells as a vehicle control. For all plates, the 
final concentration of ethanol in the medium was ≤1% total volume. During the course 
of experimentation the medium was not changed. Following incubation for the series of 
exposure times, 1 count and 3 harvest wells, and 2 count and 12 harvest wells, from 6-
well and 24-well plate respectively, were photographed from control and treatment 
plates which were then counted (as described in 2.1.3) and placed on ice. Subsequently 
the treatment and control wells from the 6 and 24-well plates were quenched and 
harvested as described below.  
Cells were harvested from the plate at each time interval. The medium in the wells was 
removed and the cells washed with 1 mL of 4ºC PBS, taking care to avoid disturbing 
the adherent cell layer. The PBS wash was removed and 100 µL of fresh 4ºC PBS was 
added to each well to quench the cells. Cells were scraped from the well into the PBS 
using a rubber cell scraper. The PBS cell suspension from each well was collected into a 
2.0 mL lysis tube and put on ice. Once cells from the plate were harvested, samples 
were frozen at -80ºC. When cells from all time points were collected and frozen, they 
were freeze-dried using a Labconco FreeZone 2.5 Plus Freeze Dry System (Kansas 
City, USA), over approximately 12-24 hours. All tubes were snap-frozen in liquid 
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nitrogen prior to freeze-drying to prevent thawing. Once dry, tubes were stored at -80ºC 
until extraction (see section 2.5.1). For each well that was harvested on a 6-well plate, in 
order to get comparable volumes of cellular material, 4 wells were harvested and pooled 
from a 24 well plate.  
2.4 Differentiation analysis and malaoxon exposure 
Confluent SH-SY5Y cells at passage 50 were seeded 1:4 on 6-well plates in 1:1 
DMEM:Hams media and incubated for 48 hours to settle and adhere to the wells (See 
workflow in Figure 2.4). Plates consisted of control and treatment that contained harvest 
wells and count wells (n=5 total count wells/treatment type). RA solution was freshly 
prepared from stock aliquots and diluted with 100% ethanol. RA was added to the 
treatment wells to a final concentration of 10 µM. The same volume of ethanol solution, 
10 µL, was added to the medium of the control wells as a vehicle control. For all plates, 
the final concentration of ethanol in the medium was ≤1% total volume. During the 
course of experimentation the medium was not changed. After 96 hours incubation, 
malaoxon was added to half of the control and half of the treatment plates to a final 
concentration of 1 µM. 
This concentration of malaoxon was chosen as it has been used on the same or similar 
cell lines in previous pesticide cytotoxicity studies which resulted in a reduction in cell 
viability in comparison to the control of 50% or less (Balbuena et al. 2010), including a 
study in this lab (Meikle, unpublished). Following incubation for a total of 120 hours, 5 
wells each for control, control+malaoxon, RA, RA+malaoxon, were photographed and 
counted in order to determine cell count and viability (as described in 2.1.3) and placed 
on ice. Subsequently 10 wells were quenched and harvested from each replicate type, as 
described previously. 
42 
 
2.5 Metabolomic analysis 
2.5.1 Extraction 
Prior to metabolomic analysis, it is necessary to breakdown the cell membrane and 
separate cellular material from metabolites in solution. Extraction of metabolites 
involves centrifuging freeze dried samples to form a pellet and adding 500 µL of 
extraction solution to each. The extraction solution was composed of 
13
C6-sorbitol 
(ISTD) in methanol at 2.6 µg/mL. 
13
C6-sorbitol was used as the internal standard as it is 
not naturally occurring and therefore can be easily distinguished from biological 
compounds. Samples were vortexed and then extracted with a Bertin Technologies 
Precellys 24 Lysis and Homogenisation tissue lyser (Aix-en-Provence, France) at 6500 
rpm for 2 x 20 seconds. All extracted samples were centrifuged at 16,100 x g for 10 
minutes using an Eppendorf 5415R centrifuge (North Ryde, Australia), after which 350 
µL of supernatant was transferred to fresh 1.5 mL tubes. Approximately 75% of the 
methanol was evaporated in an Eppendorf Concentrator Plus rotary vacuum 
concentrator. 350 µL of HPLC grade water was added to the samples to facilitate 
freezing. Samples were snap-frozen using liquid nitrogen and freeze-dried. Once dry, 
the samples were stored at -80ºC until derivatisation.  
2.5.2 Derivatisation 
The process of gas chromatography requires compounds to be sufficiently volatile to 
evaporate after injection of the sample. This can require the process of chemical 
derivatisation prior to analysis. Derivatisation involves transformation of chemical 
groups, increasing volatility and subsequently improving the quality of separation in the 
gas chromatography process, as well as increasing the number of compounds identified 
(Armitage and Barbas 2014).  The freeze dried extracts were methoximated with 20 µL 
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of  methoxyamine hydrochloride (20 mg/mL in pyridine), via agitation for 90 minutes at 
1200 rpm and 30°C using an Eppendorf Thermomixer Comfort (North Ryde, Australia). 
Methoxyamine reacts with carbonyl groups forming an oxime derivative (CH3ON) 
thereby stabilising the compound for derivatisation (Sellers 2007). Samples were then 
centrifuged for 1 minute. MSTFA was added to extracts causing trimethylsilylation by 
agitation for 30 minutes at 300 rpm and 37°C. MSTFA derivatises functional groups by 
silylation through reacting with groups on the compound to form a trimethylsilyl 
derivative (Sellers 2007). Samples were transferred to 2 mL GC vials with 200 µL 
inserts. To allow retention time locking, which facilitates identification of metabolites, 
and to monitor reproducibility, 5 µL of n-alkanes in hexane was added to all sample 
vials and capped. Immediately after derivatisation, the samples were loaded onto the 
GC-MS to be analysed. 
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Figure 2.3. Simplified workflow for RA-induced differentiation of the SH-SY5Y neuroblastoma cells 
using the optimised parameters, followed by harvesting, extraction, derivatisation, GC-MS analysis 
and data analysis (as detailed in section 2.3). 
EVE automatic cell counter 
1 well from 6-well plates, 2 wells from 24-well 
plates 
Cell Culture 
Treatment 
6-well and 24-well plates seeded from 
flasks at a 1:4 seeding density 
Left to settle for 48 hours 
10 µM retinoic acid was added to 
treatment plates 
Incubated for 0, 24, 48, 72, 96, 
120 and 144 hours 
Cells photographed and counted 
Harvesting 
After 120 hours 12 wells harvested/24-well 
plate and 3 wells harvested/6-well plate  
Cells were washed and quenched with 4°C PBS, scraped 
and collected in 2 mL lysis tubes. Samples snap frozen 
with liquid nitrogen and freeze dried 
Extraction 
Derivatisation 
Extracted using methanol solution containing 13C6-sorbitol 
internal standard. Metabolites extracted using tissue lyser. 
Solvent evaporated in rotary vacuum and replaced with water. 
Extracted samples snap frozen with liquid nitrogen and freeze 
dried 
GC-MS Analysis Data Analysis 
Analysed using the Shimadzu 2010 Plus 
GC-MS 
Methoxyamine and silylation based 
derivatisation using MSTFA 
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EVE automatic cell counter 
5 wells from each treatment group 
 
Cell Culture 
Treatment 
6-well plates seeded from 
flasks at a 1:4 seeding density 
Left to settle for 48 hours 
10 µM retinoic acid was added to 
treatment plates 
Incubated for 120 hours total Cells photographed and counted 
Harvesting 
After 120 hours, 10 wells/treatment were washed and 
quenched with 4°C PBS, scraped and collected in 2 mL 
lysis tubes. Samples snap frozen with liquid nitrogen 
and freeze dried 
Extraction 
Derivatisation 
Extracted using methanol solution containing 13C6-sorbitol 
internal standard. Metabolites extracted using tissue lyser. 
Solvent evaporated in rotary vacuum and replaced with water. 
Extracted samples snap frozen with liquid nitrogen and freeze 
dried 
GC-MS Analysis Data Analysis 
Analysed using the Shimadzu 2010 
Plus GC-MS 
Methoxyamine and silylation based 
derivatisation using MSTFA 
Figure 2.4. Simplified workflow for RA-induced differentiation and exposure to malaoxon of the SH-SY5Y 
neuroblastoma cells using the optimised parameters, followed by harvesting, extraction, derivatisation, GC-
MS analysis and data analysis (as detailed in section 2.4). 
After 96 hours 1µM concentration of 
malaoxon was added to half of the 
treatment and control plates 
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2.5.3 Instrumental analysis 
Untargeted metabolomic analyses were performed using a Shimadzu 2010 Plus gas 
chromatograph coupled to a Shimadzu QP 2010 single quadrupole mass selective 
detector (NSW, Australia), using an established method with parameters optimised for 
metabolomic analysis. Samples were injected using a Shimadzu AOC-20i autosampler 
equipped with a 10 µL syringe. The injector was programmed with 5 pre-injection 
methanol washes, a 1 µL sample injection and 5 post-injection methanol washes. Cell 
samples were randomised, with a QC sample run every fifth injection to ensure drift 
was not occurring from batch to batch, and a methanol blank was also run as every fifth 
sample. The GC inlet was equipped with a SGE FocusLiner deactivated inlet liner with 
glass wool (SGE Analytical Science) and set at 230°C in split-less mode. The carrier 
gas used in the GC was ultra-high purity helium (BOG Gases) with a flow rate of 
0.8mL/min that was retention time locked to the C19 n-alkane, such that it eluted 
between 30.32-30.36 minutes. The column used was an Agilent FactorFour VF5-5ms 
fused silica capillary column (38.5 m long, 0.25 um thickness, 0.25 mm diameter, 
including an initial 10m EZ-guard deactivated column section). The oven temperature 
was programmed with an initial temperature of 70 °C which increased at a rate of 
1°C/min for 6 minutes, then 5.63°C/min to reach a final temperature of 330°C for 10 
minutes. The transfer line was set to 300°C. After an 8-minute solvent delay, eluting 
analytes were exposed to electron impact (EI) ionisation with the ion source set to 
200°C and 70 eV. The MS was set to a scan rate of 10 scans per second and ion masses 
were scanned in the range of m/z 40-600. 
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2.5.4 Data analysis 
GC-MS data was imported into and deconvoluted using Analyzer Pro v5.0 
(SpectralWorks, Runcorn UK). The data was normalised to peak area of the internal 
standard 
13
C6- sorbitol. Raw and normalised peak areas for the identified metabolites 
were exported as a data matrix spreadsheet. Manual assessment of the matrix was 
carried out to check the quality of the metabolite library matches. For both data sets, 
metabolites were retained if they were present in ≥60% of replicates in one sample 
group. This threshold was chosen to account for any replicates that may have produced 
fewer features due to derivatisation or extraction issues. Once manually checked, the 
peak areas were further normalised to the total cell count calculated for each sample.  
The resulting matrix was exported into The Unscrambler X (v10.3) (CAMO Software, 
Oslo Norway) for comparison between the different treatment groups. The matrix was 
log10 transformed before carrying out principal component analysis (PCA) (using non-
iterative partial least squares algorithm, cross validation and no rotation). PCA scores 
plots produced were used to identify trends between treatment groups, while loadings 
plots identified the metabolites most responsible for the variation illustrated in the 
scores plots. Significant differences (p-values) in the peak areas (normalised to cell 
count) of the most variable metabolites between treatment groups were calculated using 
the non-parametric Mann-Whitney U-test following log10 (x+1) transformation using 
SPSS (IBM SPSS Statistics 21). This test was chosen as it makes fewer assumptions 
about the data and is used when data are not normally distributed. This is appropriate 
due to the small sample sizes of these data sets.  
Identification of metabolites was achieved by comparing mass spectrum and retention 
index information to that stored in the in-house library of metabolite standards 
(Metabolomics Australia, Murdoch University node, WA Australia), and to the National 
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Institute of Standards and Technology (NIST) (v2.0) mass spectral library. This would 
be considered a match if a metabolite was consistently matched to the same compound 
with at least a 700 forward match and a 20% probability.  Compounds not identified 
were added to the in-house library as unknowns in order to achieve an untargeted 
analysis. If the metabolite could not be definitively matched to a compound, but could 
be matched to a particular class it would be labelled unidentified carbohydrate, amino 
acid or fatty acid. If unable to class match, it would be labelled as unknown_retention 
index_retention time. 
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3. Results 
3.1 Optimisation of differentiation 
Prior to metabolomic analysis, optimised conditions were determined in order to 
successfully differentiate the SH-SY5Y neuroblastoma cells with RA. This was 
necessary as there is a broad range of published conditions for differentiating this cell 
line with RA. 
3.1.2 Seeding density 
Optimal seeding density was examined by testing the effect of three different seeding 
densities on control and RA-treated SH-SY5Y neuroblastoma cell growth, density and 
morphology. SH-SY5Y neuroblastoma cells were seeded at densities of 1:2, 1:4 and 1:6 
as a proportion of the flask used to seed one plate, and exposed to 10 µM RA for 24, 48, 
72, 96, 120 and 144 hours. Control cells were given the same treatment (except the RA) 
and kept in the same conditions for the same duration. Photographs of control and 
treatment cells were taken at 0, 24, 48, 72, 96, 120 and 144 hours, to document the 
morphological changes resulting from RA exposure (Figure 3.1). When exposed to     
10 µM RA, changes in morphology saw an outgrowth of neurites and slowing of the 
growth rate which changed between the seeding densities, and in comparison to the 
control (Figures 3.2-3.4).  
3.1.2.1 Cell density and morphology 
Figure 3.1 shows that for a 1:2 seeding density at 48 and 96 hours post RA exposure, 
the cells had a high and roughly equal density that had decreased by 144 hours. There 
was also the appearance of dead cells by 144 hours. For the 1:4 seeding density, cell 
density increased from 48 to 96 hours post RA exposure, but had decreased by 144 
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hours. There was also the appearance of clumps of dead cells at the final time point. For 
the 1:6 seeding density, cell density was roughly equal at 48 and 96 hours, while by 144 
hours the cell density had decreased. Dead cells could be seen at 96 and 144 hours. For 
all seeding densities, there was an overall trend of decreasing cell density from 96-144 
hours post RA exposure. The data also illustrates a change in morphology over time; 
from a more rounded cell type, to an elongated cell type with increasing neurite length 
with increasing cell to cell connections. The control cells for the 1:2 seeding density 
showed a high density at each time point, whereas in comparison the control cells for 
the 1:4 and 1:6 seeding densities had relatively high cell densities which by 144 hours 
had decreased. 
Figure 3.2 shows that the control for the 1:2 seeding density steadily increased to 
2.75x10
6
 cells/mL (±3.3x10
5
) by 120 hours, and by 144 hours had decreased to 
1.98x10
6
 cells/mL (±3.5x10
5
). Cells exposed to RA increased until 96 hours where the 
average cell count was 2.65x10
6
 cells/mL (±5.2x10
5
) and decreased to 9.37x10
5
 
cells/mL (±2.0x10
5
) at 144 hours. At 1:2 seeding density RA treatment only showed a 
significant difference to control at 144 hours post RA exposure (p<0.05).Expressed as a 
percentage of control, data for RA treatment at 1:2 seeding density showed no clear 
trend between 0-96 hours with values between 80-100%. The percentage decreased to 
73.64% by 120 hours and 47.47% by 144 hours.  
Figure 3.3 shows that the control for the 1:4 seeding density steadily increased until 120 
hours where the average cell count was 2.15x10
6
 cells/mL (±2.4x10
5
) and by 144 hours 
had decreased to 1.58x10
6
 cells/mL (±1.6x10
5
). The cells exposed to RA showed a 
small increase until 48 hours where the average cell count was 1.08x10
6
 cells/mL 
(±2.4x10
5
), after which cell density remained steady until a drop at 144 hours to 
2.72x10
5
 cells/mL (±3.6x10
4
). At 1:4 seeding density, RA treatment only had a 
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significant difference to the control at 144 hours post RA exposure (p<0.05). Expressed 
as a percentage of control, data showed a decreasing trend from 0 until 144 hours where 
the RA treatment was 17.30% of the control.  
Figure 3.4 shows that the control for the 1:6 seeding density increased until 120 hours 
where the average cell count was 1.52x10
6
 cells/mL (±1.9x10
5
). By 144 hours, cell 
density decreased to 9.85x10
5
 cells/mL (±1.1x10
5
). Cells exposed to RA steadily 
increased until 48 hours to an average cell count of  6.95x10
5
 cells/mL (±1.2x10
5
) and 
remained steady until decreasing at 144 hours to 2.1x10
5
 cells/mL (±3.9x10
4
). At 1:6 
seeding density, RA treatment only had a significant difference to the control at 120 and 
144 hours post RA exposure (p<0.05). Expressed as a percentage of control, RA 
treatment was above 100% until 48 hours where the treatment was 110.76% of the 
control. From 72-144 hours there was a decreasing trend from 78.96% to 21.32%.  
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Figure 3.1. Photographs taken of control and RA treated SH-SY5Y neuroblastoma cells at 48, 96, and 144 hours 
post exposure to 10 µM RA, using 1:2, 1:4 and 1:6 seeding densities at 100x. Scale bar indicates 50 µm. 
 
 
1:4 
C 
1:2 
C 
53 
 
 
 
0.00E+00
5.00E+05
1.00E+06
1.50E+06
2.00E+06
2.50E+06
0 24 48 72 96 120 144
A
ve
ra
ge
 c
e
ll 
co
u
n
t/
m
L 
Hours 
1:4 Control
1:4 Retinoic Acid
0
20
40
60
80
100
120
0 24 48 72 96 120 144
P
e
rc
e
n
ta
ge
 o
f 
co
n
tr
o
l 
Hours 
Treatment as a
percentage of control
Figure 3.3. Control and RA treated SH-SY5Y neuroblastoma average cell count expressed as cells/mL (left) and 
treatment as a percentage of control (right) over 144 hours using a 1:4 seeding density and 10 µM concentration of 
RA. Errors bars represent the standard error of the mean. Star denotes a significant difference (P<0.05) between 
control and treatment groups as determined by a student’s T-test. 
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Figure 3.2. Control and RA treated SH-SY5Y neuroblastoma average cell count expressed as cells/mL (left) and 
treatment as a percentage of control (right) over 144 hours using a 1:2 seeding density and 10 µM concentration of 
RA. Errors bars represent the standard error of the mean. Star denotes a significant difference (P<0.05) between 
control and treatment groups as determined by a student’s T-test. 
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Figure 3.4. Control and RA treated SH-SY5Y neuroblastoma average cell count expressed as cells/mL (left) and 
treatment as a percentage of control (right) over 144 hours using a 1:6 seeding density and 10 µM concentration of 
RA. Errors bars represent the standard error of the mean. Star denotes a significant difference (P<0.05) between 
control and treatment groups as determined by a student’s T-test. 
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3.1.3 Retinoic acid concentration 
Optimal RA concentration for differentiation was examined by testing the effect of a 
range of RA concentrations on SH-SY5Y neuroblastoma cell growth and morphology 
due to differentiation. SH-SY5Y neuroblastoma cells were exposed to 4 different 
concentrations of RA; 1, 5, 10 and 20 µM for exposures of 24, 48, 72, 96, 120 and 144 
hours. Control cells were given the same treatment (except the RA) and kept in the 
same conditions for the same duration. Photographs of the control and treatment cells 
were taken at 0, 24, 48, 72, 96, 120 and 144 hours, to document the morphological 
changes resulting from RA exposure (Figure 3.5). When exposed to the 1, 5, 10 and 20 
µM concentrations of RA, morphological change resulted in outgrowth of neurites and 
slowing of the growth rate which changed between the concentrations and in 
comparison to the control (Figures 3.6-3.9).  
3.1.3.1 Cell density and morphology 
Figure 3.5 shows that cells exposed to 1µM RA increased in density from 48 to 96 
hours post RA exposure, and by 144 hours the cell density had decreased. Cells exposed 
to 5 and 10 µM showed roughly equal density from 48 to 96 hours, while decreasing by 
144 hours. Cells exposed to 20 µM RA showed a steady decrease in density over the 
time points. For 10 and 20 µM RA at 144 hours, dead cells were present. Comparing the 
cell density between different concentrations of RA used, there is a pattern of decreased 
cell density as the concentration of RA increased. The data also illustrates a change in 
morphology over time; from a more rounded cell type, to an elongated cell type with 
increasing neurite length that make increasing cell to cell connections. In comparison, at 
48 and 96 hours the control had relatively high cell densities which by 144 hours had 
slightly decreased.  
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Figures 3.6 to 3.9 show that over the period of 0-96 hours, the control cells steadily 
increased in average cell count to 1.83x10
6 
cells/mL (±8.5x10
4
). By 144 hours, the 
average cell count dropped to 1.33x10
6 
cells/mL (±1.7x10
5
). Cells exposed to 1 and         
5 µM, RA increased up to 72 hours where the average cell count was 1.95x10
6
 
(±2.0x10
5
) and 1.83x10
6
 cells/mL (±3.2x10
5
) respectively, followed by stable average 
cell count for the two following time points, decreasing by 144 hours to 9.45x10
5
 
(±9.4x10
4
) and 7.65x10
5
 cells/mL (±9.7x10
4
) respectively. Both 1 and 5 µM 
concentrations were significantly difference to the control at 96 and 144 hours (p<0.05). 
Cells exposed to 10 µM RA increased in average cell count to 1.48x10
6
 cells/mL 
(±1.5x10
5
) at 24 hours and stayed approximately the same for the following four time 
points, decreasing by 144 hours to 4.56x10
5
 cells/mL (±5.7x10
4
). For 10 µM RA, there 
was a significant difference at 96 and 144 hours between the control and treatment cells 
(p<0.05). Cells exposed to 20 µM RA increased in average cell count to 1.33x10
6
 
cells/mL (±7.5x10
4
) at 24 hours and stayed approximately the same until 72 hours at 
1.54x10
6
 cells/mL (±4.9x10
5
), followed by a steady decrease until 144 hours at 
3.08x10
5
 cells/mL (±5.1x10
4
). For 20 µM RA, there was a significant difference at 96 
and 144 hours between the control and treatment cells (p<0.05). As the RA 
concentration increased, there was a trend of decreasing cell count.  
Figures 3.6 to 3.9 illustrate treatment as a percentage of the control. 1 and 5µM RA 
concentrations had relatively high percentages for all time points with no clear trend. By 
144 hours both had decreased to 71.32% and 57.74% respectively. For cells exposed to 
10 and 20 µM concentrations of RA, there was a general trend of decreasing percentage 
as exposure time to RA increased. By 144 hours both have decreased to 34.53% and 
23.21% respectively. 
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Figure 3.5. Photographs taken of RA treated and control SH-SY5Y neuroblastoma cells at 48, 96, and 
144 hours post exposure using 1, 5, 10 and 20 µM concentrations of RA and a 1:4 seeding density at 
100x. Scale bar indicates 50 µm. 
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Figure 3.7.Control and RA treated SH-SY5Y neuroblastoma average cell count expressed as cells/mL (left) and 
treatment as a percentage of control (right) over 144 hours using a 1:4 seeding density and a 5 µM concentration of 
RA. Errors bars represent the standard error of the mean. Star denotes a significant difference (P<0.05) between 
control and treatment groups as determined by a student’s T-test. 
 
Figure 3.6. Control and RA treated SH-SY5Y neuroblastoma average cell count expressed as cells/mL (left) and 
treatment as a percentage of control (right) over 144 hours using a 1:4 seeding density and a 1 µM concentration of RA. 
Errors bars represent the standard error of the mean. Star denotes a significant difference (P<0.05) between control and 
treatment groups as determined by a student’s T-test. 
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Figure 3.9. Control and RA treated SH-SY5Y neuroblastoma average cell count expressed as cells/mL (left) and 
treatment as a percentage of control (right) over 144 hours using a 1:4 seeding density and a 20 µM concentration of 
RA. Errors bars represent the standard error of the mean. Star denotes a significant difference (P<0.05) between 
control and treatment groups as determined by a student’s T-test 
 
Figure 3.8. Control and RA treated SH-SY5Y neuroblastoma average cell count expressed as cell count/mL (left) and 
treatment as a percentage of control (right) over 144 hours using a 1:4 seeding density and a 10 µM concentration of 
RA. Errors bars represent the standard error of the mean. Star denotes a significant difference (P<0.05) between control 
and treatment groups as determined by a student’s T-test. 
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3.2 Analysis of differentiation in 6- and 24-well plates 
Metabolomic analysis has typically been carried out using cells grown in 6-well plates, 
as it achieves an appropriate mass of cells for analysis. Whilst most previous 
experiments in this research group using SH-SY5Y cells in both plate types have been 
24-48 hours in duration. Cells can also easily be cultured in 24-well plates, and some 
differences in growth behaviour have been observed. For this reason, differentiation 
using the optimised parameters was examined in both 6 and 24-well plates. This 
comparison would allow the most appropriate growth conditions for differentiation to 
be determined. This experiment was also carried out over multiple time points to 
determine which time point would be the focus of the subsequent experiment.  
SH-SY5Y neuroblastoma cells were seeded at a density of 1:4 and exposed to 10 µM 
RA in 6 and 24-well plates, and the metabolites profiled using GC-MS. Cells were 
exposed to RA for 24, 48, 72, 96, 120 and 144 hours. Control cells were given the same 
treatment (except the RA) and kept in the same conditions for the same duration. 
Immediately before cells were harvested for metabolomics analysis at 24, 48, 72, 96, 
120 and 144 hours, photographs were taken to document the morphological changes 
resulting from RA exposure (Figure 3.10). One well from each 6-well plate and 2 wells 
from each 24-well plate were counted (Figure 3.11 and 3.12). Three wells from each 6-
well plate, and 12 from each 24-well plate were harvested for metabolomic analysis. 
When exposed to 10 µM RA, morphologically the cells grew longer neurites and the 
growth rate slowed in both plate types (Figures 3.10-3.12).  
3.2.1 Cell density and morphology 
Figure 3.10 shows that control cells plated in 6-well plates decreased in cell density 
between 48, 96 and 144 hours. The cells plated in 6-well plates exposed to RA 
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increased in density at each time point sampled. In both 96 and 144 hours dead cells 
were present. Control cells plated in 24-well plates showed an increase in density from 
48 to 96 hours, but by 144 hours had decreased in density. Cells plated in 24-well plates 
exposed to RA had roughly the same density between 48 and 96 hours before 
decreasing by 144 hours. In both 24-well control and treatment at 96 and 144 hours 
dead cells were present. The morphology of cells exposed to RA over the time points in 
both plate types illustrates a change from a more rounded cell type, to an elongated cell 
type with increasing neurite length that made increasing cell to cell connections. 
Figure 3.11 shows that the control in the 6-well plates decreased from 48 until 96 hours 
to 1.00x10
6
 cells/mL, before increasing at 120 hours to 1.6x10
6
 cells/mL then 
decreasing again at 144 hours to 9.90x10
5
 cells/mL. The cells exposed to RA showed a 
decreasing trend in cell density from 0 to 144 hours with a final average cell count of 
2.90x10
5
 cells/mL. Expressed as a percentage of control, RA treatment showed a 
decreasing trend from time 0 until 120 hours where the treatment was 20.00% of the 
control, with a slight increase in percentage to 29.30% at 144 hours. 
Figure 3.12 also shows that the control in the 24-well plates slightly increased until 120 
hours to an average cell count of 1.35x10
6
 cells/mL, before slightly decreasing at 144 
hours to 1.30x10
6
 cells/mL. Cells exposed to RA decreased until 72 hours to an average 
cell count of 4.55x10
5
 cells/mL, and increased by 144 hours to 7.15x10
5
 cells/mL. 
Expressed as a percentage of control, RA treatment showed a decreasing trend from 0 to 
72 hours where the treatment was 47.15% of the control, with the percentage slightly 
increasing and becoming stable at the last two time points with percentages of 57.41% 
and 55.00% respectively. No significance testing was carried out as only one well from 
each 6-well plate and 2 wells from each 24-well plate were counted to be used for 
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normalisation of data, with the remaining wells required to achieve adequate cell mass 
for metabolomic analysis. 
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 Figure 3.10. Photographs taken of RA treated and control SH-SY5Y neuroblastoma cells at 48, 96, and 
144 hours post exposure using a 10 µM concentration of RA and a 1:4 seeding density plated in 6 and 
24-well plates at 100x. Scale bar indicates 50 µm. 
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Figure 3.12. Control and RA treated SH-SY5Y neuroblastoma average cell count expressed as cells/mL (left) and 
treatment as a percentage of control (right) over 144 hours using a 1:4 seeding density in 24-well plates using a 10 µM 
concentration of RA. Errors bars represent the standard error of the mean 
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Figure 3.11. Control and RA treated SH-SY5Y neuroblastoma cell count expressed as cells/mL (left) and treatment as a 
percentage of control (right) over 144 hours using a 1:4 seeding density in 6-well plates a 10 µM concentration of RA.  
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3.2.2 Metabolomic analysis 
Metabolomic analysis using GC-MS was used to compare changes in intracellular 
metabolites in control and RA-treated cells in 6 and 24-well plates. Figure 3.13 shows 
the PCA scores plot for cell samples analysed following exposure to 10 µM RA in 6 and 
24-well plates, and the corresponding intracellular metabolite loadings plot. All time 
points and replicates are included for control and treatment in both plate types to show 
the distribution of sample groups. Variation between groups is best described by 
principal component 1 (PC-1) which explains 24% of the variance and is responsible for 
separation of control and RA treatment groups. The results show grouping dependent on 
treatment type, not plate type, and investigation of all seven PC’s generated by this 
analysis confirmed that none were able to separate the data based on plate type. The 
corresponding loadings plot (B) is a graphical representation of the individual 
metabolites most responsible for the variation seen in the PC scores plot.  
As previous analysis revealed no major differences between cells grown in 6 and 24-
well plates, subsequent analysis of change over time used only data from 6-well plates. 
Figure 3.14 shows the PCA scores plot for cell samples analysed following exposure to 
10 µM RA in 6-well plates, and the corresponding intracellular metabolite loadings plot. 
All time points and replicates are included for control and treatment. The results show 
clear grouping between treated and untreated cells, except for RA-treated cells at 24 and 
48 hours which are grouped with the control cells indicating less variation between 
these groups. PC-1 explains 44% of the variance, and is the PC most responsible for 
separation of control and treatment groups. The corresponding loadings plot (B) depicts 
the metabolites most responsible for the variation seen in the PC scores plot.  
In order to further explore the data, different sub-groups were compared using PCA. 
Figure 3.15 shows the PCA scores plots for cell samples analysed following exposure to 
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RA for 24 (A) and 48 (B) hours in 6-well plates, compared to untreated cells. RA-
treated cells are clearly separated from control cells in both scores plots (A and B), 
except for one RA-treated replicate at 24 hours which has been grouped with the 
control. One of the three control replicates at 24 hours in 6-well plates was unable to be 
included due to experimental error. In plot A, PC-2 explains 25% of the variance and is 
the primary PC responsible for separation of control and treatment at 24 hours. In plot 
B, variation between control and treatment groups at 48 hours is described by PC-2, 
which explains 21% of the variance, and PC-3, which explains 11% of the variance. 
Figure 3.16 shows the PCA scores plots for the cell samples analysed following 
exposure to RA for 72 (A) and 96 (B) hours in 6-well plates compared to untreated 
cells. RA-treated cells are tightly grouped and separate from control cells in plot A. 
Separation of control and treatment is also clearly visible after 96 hours in plot B. In 
plot A, PC-1explains 41% of the variance and is the primary PC responsible for 
separation of control and treatment. In plot B, PC-1 explains 55% of the variance and 
PC-2 explains 21% of the variance and together they are responsible for the separation 
of control and treatment groups at 96 hours.  
Figure 3.17 shows the PCA scores plot for cell samples analysed following exposure to 
RA for 120 (A) and 144 (B) hours in 6-well plates compared to untreated cells. RA-
treated cells are clearly separated from the control cells at both time points. In plot A, 
PC-1 explains 77% of the variance and is the PC most responsible for the separation of 
control and treatment groups at 120 hours. In plot B, PC-1 explains 59% of the variance 
and is also the primary PC responsible for separation of control and treatment at 144 
hours. The sub-group comparison has identified that there were differences in 
metabolite profile between control and treatment at all time points, while the overall 
model suggests that these differences became greater at the later time points. 
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Figure 3.13. A-Principal component scores plot showing variation in intracellular metabolites derived 
from SH-SY5Y cells exposed to 10 µM RA at a 1:4 seeding density plated in 6 and 24-well plates at 
24, 48, 72, 96, 120 and 144 hours, against untreated cells. Grouping of treatment sample sets is 
represented by coloured ovals (blue=control 6-well plates, green=control 24-well plates, red=RA 6-
well, grey=RA 24-well). n=3 for each treatment group. B represents the corresponding loadings plot.  
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Figure 3.14. A-Principal component scores plot showing variation in intracellular metabolites derived 
from SH-SY5Y cells exposed to 10 µM RA at a 1:4 seeding density plated in 6-well plates at 24, 48, 72, 
96, 120 and 144 hours, against untreated cells. Grouping of treatment sample sets is represented by 
coloured ovals (blue=control, red=RA). n=3 for each treatment group. B represents the corresponding 
loadings plot.  
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Figure 3.15. Principal component scores plot showing variation in intracellular metabolites derived 
from SH-SY5Y cells exposed to 10 µM RA at a 1:4 seeding density plated in 6-well plates at 24 (A) 
and 48 (B) hours, against untreated cells. Grouping of treatment sample sets is represented by 
coloured ovals (blue=control, red=RA). n=3 for each treatment group. 
 
A 
B 
69 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16. Principal component scores plot showing variation in intracellular metabolites derived from 
SH-SY5Y cells exposed to 10 µM RA at a 1:4 seeding density plated in 6-well plates at 72 (A) and 96 
(B) hours, against untreated cells. Grouping of treatment sample sets is represented by coloured ovals 
(blue=control, red=RA). n=3 for each treatment group. 
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Figure 3.17. Principal component scores plot showing variation in intracellular metabolites derived from 
SH-SY5Y cells exposed to 10 µM RA at a 1:4 seeding density plated in 6-well plates at 120 (A) and 144 
(B) hours, against untreated cells. Grouping of treatment sample sets is represented by coloured ovals 
(blue=control, red=RA). n=3 for each treatment group. 
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The information collected from the loading plots for each time point of exposure to RA 
compared to the control produced a list of intracellular metabolites which most 
contributed to the variance observed between groups. These lists were combined and 
analysed for any observable trends and significant changes over the time points.  
Table 3.1 illustrates the fold changes seen in the normalised peak area of intracellular 
metabolites due to exposure to RA at 24, 48, 72, 96, 120 and 144 hours, and whether 
these changes were significant (p<0.05). The data shows a general decrease in the level 
of amino acids, although alanine, norleucine, L-proline, L-threonine and L-valine 
increased at 48 and/or 120 hours, with only the increase in L-proline having significant. 
The data also shows an increasing trend in the level of the carbohydrates and fatty acids 
over time with all except unidentified carbohydrate 2 having significance (p<0.05). 
There were various increases and decreases in the metabolite levels in other and 
unknown compounds, with the majority of significant changes occurring at 120 and 144 
hours. The metabolites with significant differences, particularly at 120 hours, were used 
to investigate the biochemical pathways involved and therefore how exposure to RA, 
and hence differentiation, affected cellular metabolism. Details of this investigation are 
discussed in section 4.2.3. 
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Metabolites 24 hr 48 hr 72 hr 96 hr 120 hr 144 hr 
Amino acids 
Alanine, phenyl-,TMS ester 0.85 ⬇ 0.69 ⬇ 0.81 ⬇ ⬇ 1.26 ⬆ ⬇ 
DL-Norleucine, ethyl ester ⬆ 1.09 ⬆ 0.99 = ⬇ 1.43 ⬆ ⬇ 
Glycine, 3TMS_1312_17.71 0.98 ⬇ 0.94 ⬇ 0.61 ⬇ 0.31 ⬇ 0.67 ⬇ 0.67 ⬇ 
L-Isoleucine, 2 
TMS_1298_17.37 
0.74 ⬇ 0.66 ⬇ ⬇ * ⬇ ⬇ ⬇ 
L-Proline, 5-oxo-1-(TMS)-, TMS 
ester 
0.99  = 1.00 = 0.92 ⬇ * 0.95 ⬇ 1.22 ⬆ * 1.09 ⬆ * 
L-Threonine, O-(TMS)-, TMS 
ester 
1.02 ⬆ 1.05 ⬆ 0.85 ⬇ 0.60 ⬇ 1.09 ⬆ 0.69 ⬇ 
L-Valine, N-(TMS)-TMS ester 0.72 ⬇ 1.01 ⬆ ⬇ ⬇ ⬇ 0.59 ⬇ 
N,O,O-Tris (TMS)-L-Threonine 0.90 ⬇ 0.46 ⬇ ⬇ 0.33 ⬇ 0.99 = 0.84 ⬇ 
2-Pyrrolidone-5-carboxylic acid, 
TMS ester 
⬆ 0.62 ⬇ 0.60 ⬇ 0.72 ⬇ ⬇ ⬇ 
Serine, bis (TMS) 1.02 ⬆ 0.95 ⬇ ⬇ * ⬇ ⬇* ⬇ 
Unidentified amino acid 1 0 0 ⬆ 0 ⬆ * ⬆ 
Carbohydrates 
D-(-)-Fructose, 
5TMS_1862_29.61 
⬆ 1.04 ⬆ 1.09 ⬆ 0.75 ⬇ 1.49⬆ * 1.19 ⬆ * 
Unidentified carbohydrate 1 1.04 ⬆ 1.05⬆ * 1.06 ⬆ 1.09 ⬆ * 1.29 ⬆ * 1.17 ⬆ * 
Myo-Inositol, 
6TMS_2181_33.39 
0.99 = 0.96 ⬇ 0.86 ⬇ * 0.85 ⬇ * 1.08 ⬆ * 1.00 = 
Unidentified carbohydrate 2 0 ⬆ ⬇ ⬇ ⬆ ⬇ 
Unidentified carbohydrate 3 1.07 ⬆ 1.06 ⬆ * 1.08 ⬆ 1.12 ⬆ 1.44 ⬆ * 1.23 ⬆ * 
Unidentified carbohydrate 4 1.87 ⬆  1.09 ⬆ 0.87 ⬇ 1.11 ⬆ 7.04 ⬆ * 1.99⬆ * 
Fatty Acids 
Decanoic acid, 
1TMS_1459_21.39 
⬆ 0.65 ⬇ 2.57⬆ * 1.89 ⬆ 3.08 ⬆ * 2.12 ⬆ 
Hexadecanoic acid, TMS ester 1.15 ⬆ * 1.04 ⬆ 0.98 ⬇ 1.22 ⬆ * 1.48 ⬆ * 1.33 ⬆ * 
Stearic acid, 1TMS_2244_35.96 1.12 ⬆ * 1.02 ⬆ 0.92 ⬇ * 1.34 ⬆ * 1.46 ⬆ * 1.42 ⬆ * 
Unidentified Fatty Acid 1 ⬆ 0.57⬇ 3.79⬆ * 3.85⬆ 6.83⬆ * 1.71⬆ 
Others/Unknowns 
1,2-Benzenedicarboxylic acid, 
mono (2-ethylhexyl) ester 
⬆ 2.01 ⬆ 2.19 ⬆ ⬆ 3.33 ⬆ * 1.69 ⬆ 
Cholesterol, 1TMS_3158_47.88 1.09 ⬆  * 1.03 ⬆ 0.96 ⬇ 0.93 ⬇ 1.14 ⬆ * 0.98 ⬇ 
Ethanamine, N-ethyl-
N[(ethylthio)methyl] 
⬆ 1.14 ⬆ ⬇ 0 ⬇ 1.20 ⬆ 
Phosphoric acid, bis(TMS) 2,3-
bis[(TMS)oxy]propyl ester 
1.08 ⬆ 0.79 ⬇ * 0.73 ⬇ * 0.47 ⬇ * 1.08 ⬆ 0.65 ⬇ 
Succinic acid, 
2TMS_1323_17.99 
⬆ ⬇ ⬇ ⬇ ⬇ ⬇ 
Unknown_1664_25.58 ⬆ ⬇ 0 ⬇ ⬇ 0 
Unknown_1841_29.09 2.08 ⬆ 0.72 ⬇ ⬇ ⬇ ⬇ ⬇ 
Unknown_1131_13.11 0.97 ⬇ 0.94 ⬇ 0.93⬇ 1.39⬆ 1.37⬆ * 1.26⬆ * 
Unknown_1360_18.77 0.76⬇ 1.12⬆ 1.02⬆ ⬆ ⬇ ⬆ 
Unknown_1424_20.40 0 0 ⬆ ⬆ ⬆ ⬆ 
Table 3.1 Fold change seen in intracellular metabolites due to exposure to 10 µM RA at 24, 48, 72, 96, 120 and 
144 hours. Green arrow indicates a fold increase and a red arrow a fold decrease in the levels of metabolites 
between control and treatment at each time point. Black arrows also indicate a metabolite increase from or 
decrease to 0. Equals sign indicates no change. n=3 for each sample group. Significant changes in the normalised 
peak area were calculated using the non-parametric Mann-Whitney U-test following log10 (x+1) transformation. 
*=p<0.05 
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Unknown_1427_20.48 1.52⬆ 1.07⬆ 1.13⬆ 1.86⬆ 1.14⬆ 4.47⬆ * 
Unknown_1468_21.54 0.88 ⬇ 0 ⬇ 0 0 0 
Unknown_1486_21.97 1.16⬆ 0.52 ⬇ ⬇* ⬇* ⬇ ⬇ 
Unknown_1519_22.66 0.67 ⬇ 0.52 ⬇ 0 ⬆ 0 ⬆ 
Unknown_1536_22.96 1.01⬆ 0.94 ⬇ 0.61 ⬇ * 0.29 ⬇ 0.85 ⬇ * 0.52 ⬇ * 
Unknown_1585_24.00 1.05⬆ 1.13⬆ 0.59 ⬇ 0 ⬇ ⬆ 
Unknown_1602_24.37 0.60 ⬇ ⬇ 0 0 ⬆ ⬆ 
Unknown_1679_25.91 ⬆* 0.82 ⬇ 0 0 0 0 
Unknown_1720_26.68 ⬆* 1.06 ⬆ ⬆ 0 0 0 
Unknown_1727_26.77 1.37 ⬆ * 1.18 ⬆ 0.55 ⬇ ⬇ ⬇ 0 
Unknown_1832_28.91 1.08 ⬆ 0.62 ⬇ ⬇* ⬇ ⬇ ⬇ 
Unknown_2492_39.39 ⬆ 1.42 ⬆ 1.47 ⬆ 1.72 ⬆ 2.83 ⬆ * ⬇ 
Unknown_2760_43.09 1.25 ⬆ 1.09⬆ 1.24 ⬆ 1.39 ⬆ 1.64 ⬆ * 1.26 ⬆ 
Unknown_2955_45.47 1.21 ⬆ * 1.06 ⬆ 1.23 ⬆ 1.33 ⬆ 1.55 ⬆ * 1.29 ⬆ 
Unknown_2977_41.93 ⬆ 0 1.21 ⬆ ⬆ 2.70 ⬆ * ⬆ 
Unknown_3146_47.69 1.17 ⬆ * 1.02 ⬆ 1.19 ⬆ 1.29 ⬆ 1.51 ⬆ * 1.46 ⬆ * 
Unknown_3152_47.76 ⬆ 1.24 ⬆ 0 ⬇ 0 ⬇ 
Unknown_3348_49.81 1.14 ⬆ * 1.07 ⬆ 1.18 ⬆ 1.25 ⬆ 1.5 ⬆ * 1.54 ⬆ * 
Unknown_3539_51.80 1.12 ⬆ 0.82 ⬇ 1.21 ⬆ 1.66 ⬆ 1.59 ⬆ * 1.54⬆ * 
Unknown_3739_53.79 0.89 ⬇ 0.88 ⬇ 1.67 ⬆ 1.25⬆ 2.23 ⬆ * 1.40 ⬆ 
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To assess whether there was a common trend in the change in metabolite levels 
following RA treatment, levels of individual metabolites were plotted. Figure 3.18 
shows the differences in the log transformed average peak area of control and RA-
treated cells at 24, 48, 72, 96, 120 and 144 hours for D-fructose and unidentified 
carbohydrates 1, 3 and 4. Aside from an increase in the control at 72 hours for 
unidentified carbohydrate 4 and a decrease in RA at 96 hours in D-Fructose, the average 
peak area for RA-treated cells remained higher than the control and showed an 
increasing trend. After 120 hours, peak area of D-fructose and unidentified carbohydrate 
4 decreased. D-fructose had a significant difference between control and treatment 
(p<0.05) at 120 and 144 hours, unidentified carbohydrate 1 at 48, 96, 120 and 144 
hours, unidentified carbohydrate 3 at 48, 120 and 144 hours, and unidentified 
carbohydrate 4 at 120 and 144 hours. 
Figure 3.19 shows the differences in the log transformed average peak area of control 
and RA-treated cells at 24, 48, 72, 96, 120 and 144 hours for the fatty acids decanoic 
acid, hexadecanoic acid, stearic acid and unidentified fatty acid 1. In contrast to the 
control, the average peak area of RA-treated cells showed an increasing trend over the 
time points, except for decanoic acid and unidentified fatty acid 1 which decreased after 
120 hours. Decanoic acid had a significant difference between control and treatment 
(p<0.05) at 72 and 120 hours, hexadecanoic acid at 72, 96, 120 and 144 hours, stearic 
acid at 24, 72, 96, 120 and 144 hours, and unidentified fatty acid 1 at 72 and 120 hours.  
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Figure 3.18. Change in average peak area between control and RA-treated SH-SY5Y neuroblastoma cells at 24, 48, 
72, 96, 120 and 144 hours in four carbohydrate compounds A, B, C and D, that showed significant difference to the 
control, n=3 for each treatment group. Errors bars represent the standard error of the mean. 
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Figure 3.19. Change in average peak area between control and RA-treated SH-SY5Y neuroblastoma cells at 24, 
48, 72, 96, 120 and 144 hours in four fatty acid compounds A, B, C and D, that showed significant difference to 
the control, n=3 for each treatment group. Errors bars represent the standard error of the mean. 
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3.3 Differentiation analysis and malaoxon exposure 
The effect of malaoxon on undifferentiated and differentiated SH-SY5Y neuroblastoma 
cells was examined by exposing the cells to 10 µM RA, followed by subsequent 
exposure to 1µM malaoxon. This also allowed further examination of the biochemical 
response to RA induced differentiation. SH-SY5Y neuroblastoma cells were seeded at a 
density of 1:4 and exposed to 10 µM RA for 120 hours. Control cells were given the 
same treatment (except the RA) and kept in the same conditions for the same duration. 
At 96 hours, half of the control and treatment replicates were exposed to1 µM of 
malaoxon for 24 hours prior to harvesting. 
Immediately before the cells were harvested for metabolomic analysis, photographs 
were taken at 120 hours to document the morphological changes resulting from RA and 
malaoxon exposure (Figure 3.20). Cell count and cell viability determination was also 
carried out. When exposed to the 10 µM RA, 10 µM RA+1 µM malaoxon, or 1 µM 
malaoxon alone, both the morphology and growth rate of the RA-treated cells changed 
(Figure 3.21).  
3.3.1 Cell density morphology 
Figure 3.20 shows that after 120 hours, the control cells and the cells exposed to 
malaoxon for 24 hours had a relatively high cell density, with the presence of dead cells. 
This was more apparent in the cells exposed to malaoxon, and the morphology of these 
cells was a more rounded cell type. After 120 hours, cells exposed to RA and 
RA+malaoxon had a lower cell density and number of dead cells, which was roughly 
equal between them. The morphology of these cells, in comparison to the control was a 
more elongated cell type with increased neurite length. 
 
78 
 
Figure 3.21 shows that the average cell count decreased in response to RA treatment 
compared to the control, from 1.56x10
6
 (±9.3x10
4
) to 1.3x10
6
 cells/mL (±1.1x10
5
) by 
120 hours. Average cell count between control cells and cells exposed to malaoxon 
count/mL increased from 1.56x10
6
 (±9.3x10
4
) to 1.62x10
6
 cells/mL (±9.7x10
4
). The 
average cell count/mL increased between cells exposed to RA and RA+malaoxon from 
1.3x10
6
 (±1.1x10
5
) to 1.4x10
6
 cells/mL (±1.4x10
5
). The average cell count/mL 
decreased from 1.62x10
6
 (±9.7x10
4
) to 1.4x10
6
 cells/mL (±1.4x10
5
) between cells 
exposed to control+malaoxon and RA+malaoxon. Average % viability decreased from 
97% to 95.6% when comparing the control and control+malaoxon treatment groups. As 
does the RA and RA+malaoxon treatment groups, with a decrease from 97.25% to 
96.2%. The % viability increases from 95.6% to 96.2% when comparing 
control+malaoxon and RA+malaoxon. There were no significant differences in average 
cell count between control v RA, control v control+malaoxon, RA v RA+malaoxon or 
control+malaoxon v RA+malaoxon. 
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Figure 3.20. Photographs of control, control+malaoxon, RA and RA+malaoxon treated SH-SY5Y 
neuroblastoma cells after 120-hour exposure to 10 µM RA and subsequent 24-hour exposure to1 µM 
malaoxon at a 1:4 seeding density at 100x. Scale bar indicates 50 µm. 
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Figure 3.21. Control, RA, control+malaoxon and RA+malaoxon treated SH-SY5Y neuroblastoma average 
cell count, and viability after 120-hour exposure to 10 µM RA and subsequent 24-hour exposure to 1 µM 
malaoxon, using a 1:4 seeding density in 6-well plates. N=10 for each treatment group. Errors bars represent 
the standard error of the mean. 
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3.3.2 Metabolomic analysis 
Metabolomic analysis using GC-MS was used to compare changes in intracellular 
metabolites to further study the effects of RA-induced differentiation and to determine 
the biochemical response of undifferentiated and differentiated SH-SY5Y cells to 
malaoxon. Figure 3.22 shows the PCA scores plot and the corresponding intracellular 
metabolite loading plot, for cells analysed following exposure to 10 µM RA, 1 µM 
malaoxon, or 10 µM RA+1 µM malaoxon against untreated cells. All replicates for all 4 
control and treatment groups are included to show the distribution of sample groups. 
Variation between groups is best described by PC-7 which explains 3% of the variance 
and PC-4 which explains 5% of the variance, which together are responsible for the 
separation of the groups. The results show a trend towards grouping based on treatment, 
but also some overlap between RA and RA+malaoxon, and control and 
control+malaoxon. The loadings plot (B) is a graphical representation of the individual 
metabolites most responsible for the variation seen in the PC scores plot. 
Figure 3.23 shows the PCA scores plot for cell samples analysed following exposure to 
10 µM RA, against untreated cells, and the corresponding intracellular metabolite 
loadings plot. The results show grouping of control and RA-treated cells. PC-5 explains 
4% of the variance and is the PC most responsible for separation of control and 
treatment groups. The loadings plot (B) is a graphical representation of the individual 
metabolites most responsible for the variation seen in the PC scores plot. The 
information collected from the corresponding loadings plot produced a list of the most 
variable intracellular metabolites between the cells exposed to RA, against untreated 
cells. This was analysed for any observable trends and significant changes. 
Table 3.2 illustrates the fold changes seen in the normalised peak area of intracellular 
metabolites due to exposure to 10 µM RA for 120 hours, against untreated cells, and 
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which changes were significant. The data shows an overall decreasing trend in the 
levels of amino acids, with only two unidentified amino acids having increased. There 
was a significant difference (p<0.05) in the levels of glycine and serine, N,O-bis (TMS) 
ester. This decreasing trend was also seen for the carbohydrate and fatty acid metabolite 
levels, with only mannose and dodecanoic acid showing an increase. In addition, the 
other/unknown metabolites overall showed a decreasing trend with butanedioic acid 
(p<0.0005), succinic acid (p<0.05) and unknown_1830_28.90 (p<0.005) among those 
with significance. The metabolites listed in Table 3.2 were used to further investigate 
the differences observed by PCA comparing control and RA-treated cells at 120 hours. 
Details of that investigation are discussed in section 4.3.1. 
Figure 3.24 shows the PCA scores plot for cell samples analysed following exposure to 
1 µM malaoxon, against untreated cells, and the corresponding intracellular metabolite 
loadings plot. The data shows some grouping of the control and treatment groups, 
although there is overlap of some of the untreated cells with the treated cells. PC-6 and 
PC-7 each explain 4 % of the variance and together are responsible for the separation of 
control and control+malaoxon. The loadings plot (B) is a graphical representation of the 
individual metabolites most responsible for the variation seen in the PC scores plot. The 
information collected from the corresponding loadings plot produced a list of the most 
variable intracellular metabolites between the cells exposed to malaoxon, against 
untreated cells. This was analysed for any observable trends and significant changes. 
Table 3.3 illustrates the fold changes seen in the normalised peak area of intracellular 
metabolites due to exposure to 1 µM malaoxon for 24 hours, against untreated cells, and 
which changes were significant. The data shows that amino acids, carbohydrates and 
fatty acids have all decreased following malaoxon exposure, with all classes containing 
some significant differences. Changes in the other/unknown metabolites varied 
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including increases in cholesterol and 2,3,4-trihydroxybutyric acid, and decreases in 
urea and unknowns including 1519_22.69 and 1849_29.24. Both of these changes in 
unknowns were significant (p<0.05). The metabolites listed in Table 3.3 were used to 
investigate the differences observed by PCA comparing control and malaoxon-treated 
cells at 120 hours. Details of this investigation are discussed in section 4.3.2.1. 
Figure 3.25 shows the PCA scores plot for cell samples analysed following exposure to 
10 µM RA for 120 hours and 1 µM malaoxon for a further 24 hours, or 10 µM RA for 
120 hours, and the corresponding intracellular metabolite loadings plot. The results 
show some grouping between treatment groups, but there is also overlap. PC-4 explains 
5% of the variance and is the PC most responsible for separation of RA and 
RA+malaoxon. The loadings plot (B) is a graphical representation of the individual 
metabolites most responsible for the variation seen in the PC scores plot. The 
information collected from the corresponding loadings plot produced a list of the most 
variable intracellular metabolites between the cells exposed to RA+malaoxon or RA. 
This was analysed for any observable trends and significant changes. 
Table 3.4 illustrates the fold changes seen in the normalised peak area of intracellular 
metabolites due to exposure to 10 µM RA for 120 hours and 1 µM malaoxon for a 
further 24 hours, or 10 µM RA for 120 hours, and which of these changes were 
significant. The data shows an overall increasing trend in the levels of amino acids and 
fatty acids, with only two amino acid metabolites showing decreases. Although, none of 
these changes were significant (p>0.05). Both carbohydrates included decreased, one 
significantly (p<0.05). The other/unknown metabolites showed variable changes in 
metabolite levels with decreases in cholesterol, ethanamine and unknown_1849_29.24, 
which was significant (p<0.05), whilst significant increases were seen in 1,2,3-
propanetricarboxylic acid (p<0.05) and unknown_1787_28.00 (p<0.005). The 
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metabolites listed in Table 3.4 were used to further investigate the differences observed 
by PCA comparing RA-treated and RA+malaoxon treated cells at 120 hours. Details of 
that investigation are discussed in section 4.3.2.2. 
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Figure 3.22. Principal component scores plot showing the variation in intracellular metabolites derived from SH-SY5Y 
cells exposed to 10 µM RA for 120 hours and 1 µM malaoxon for 24 hours, against untreated cells. Grouping of 
treatment sample sets is represented by coloured ovals (blue=control, green=RA, red=control+malaoxon, 
grey=RA+malaoxon). n=10 for each treatment group. B represents the corresponding loadings plot.  
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Figure 3.23. Principal component scores plot showing the variation in intracellular metabolites derived from SH-
SY5Y cells exposed to 10 µM RA for 120 hours, against untreated cells. Grouping of treatment sample sets is 
represented by coloured ovals (blue=RA, red=control). n=10 for each treatment group. B represents the 
corresponding loadings plot.  
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Metabolites C v RA 
Amino acids 
2-pyrrolidone-5-carboxylic acid, TMS ester 0.84 ⬇ 
Glutamate, N-(TMS)-,bis (TMS) ester 0.90 ⬇ 
Glycine, N-(TMS)-, TMS ester 0.62 ⬇ 
Glycine, N,N-bis (TMS)-, TMS ester 0.94 ⬇ * 
L-Alanine, N-(TMS)-, TMS ester 0.52 ⬇ 
L-aspartic acid, bis (TMS) ester 0.69 ⬇ 
L-Isoleucine, N-(TMS)-, TMS ester 0.74 ⬇ 
L-threonine, O-(TMS)-, TMS ester 0.91 ⬇ 
L-Valine, N-(TMS)-, TMS ester 0.79 ⬇ 
N,O,O-Tris(TMS)-L-Threonine 0.89 ⬇ 
N,O-bis (TMS)-L-phenylalanine 0.66 ⬇ 
Proline 0.91 ⬇ 
Serine, bis (TMS) 0.85 ⬇ 
Serine, N,O-bis (TMS)-, TMS ester 0.36 ⬇ * 
Tyrosine,O-TMS, TMS ester 1.14 ⬆ 
Unidentified amino acid_1274_16.67 0.59 ⬇ 
Unidentified amino acid_1419_20.31 1.18 ⬆ 
Unidentified amino acid_1180_14.34 1.00 = 
Unidentified amino acid_1305_17.43 0.87 ⬇ 
Carbohydrates 
Myo-inositol,1,2,3,4,5,6-hexakis-O-(TMS) 0.67 ⬇ 
Mannose 2,3,4,5,6-pentakis-O-(TMS) 1.09 ⬆ 
Ribitol, 1,2,3,4,5-pentakis-O-(TMS) 0.86 ⬇ 
Unidentified carbohydrate_2697_42.21 0.92 ⬇ 
Fatty Acids 
Decanoic acid, TMS ester 0.84 ⬇ 
Dodecanoic acid, TMS ester 1.04 ⬆ 
Others/Unknowns 
1,2,3-Propanetricarboxylic acid, 2-[(TMS)oxy]-, 
tris(TMS) ester 
0.51 ⬇ 
1-O-tetradecylglycerol, bis (TMS) ether ⬆ ** 
2,3,4-trihydroxybutyric acid tetrakis (TMS) 0.71 ⬇ 
Benzoic acid TMS ester 0.69 ⬇ 
Butanedioic acid, [9(TMS)oxy]-,bis (TMS) ester 0.69 ⬇ *** 
Cholesterol 0.91 ⬇ 
Ethanamine, N-ethyl-N-[(ethylthio)methyl]- 1.02 ⬆ 
Succinic acid, 2TMS_1323_17.99 0.83 ⬇ * 
Unknown_1199_14.81 1.03 ⬆ 
Unknown_1519_22.69 0.61 ⬇ * 
Unknown_1582_23.93 0.77 ⬇ 
Table 3.2. Fold changes seen in intracellular metabolites due to exposure to 10 µM RA for 120 hours, against untreated cells. 
Green arrow indicates a fold increase and a red arrow indicates a fold decrease in the levels of metabolites between control 
and treatment at each time point. Black arrows also indicate a metabolite increase or decrease from 0. Equals sign indicates no 
change. n=10 for each sample group. Significant changes in the normalised peak area were calculated using the non-
parametric Mann-Whitney U-test following log10 (x+1) transformation. *=p<0.05, **=p<0.005, *=p<0.0005 
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Unknown_1589_24.07 1.38 ⬆ 
Unknown_1667_25.61 0.83 ⬇ 
Unknown_1682_25.91 1.57 ⬆ 
Unknown_1723_26.47 0.81 ⬇ * 
Unknown_1758_27.43 1.25 ⬆ 
Unknown_1830_28.90 0.87 ⬇ ** 
Unknown_1855_29.37 0.67 ⬇ 
Unknown_1920_30.60 0.72 ⬇ 
Unknown_1954_31.17 0.76 ⬇ 
Unknown_1962_31.31 1.55 ⬆ 
Unknown_2205_35.37 0.91 ⬇ 
Unknown_2388_37.91 0.87 ⬇ 
Urea 0.79 ⬇ 
89 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.24. Principal component scores plot showing the variation in intracellular metabolites derived from SH-
SY5Y cells exposed to 1 µM malaoxon for 24 hours, against untreated cells. Grouping of treatment sample sets is 
represented by coloured ovals (blue=control, red=control+malaoxon). n=10 for each treatment group. B represents 
the corresponding loadings plot.  
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Metabolites C v C+M 
Amino acids 
DL-Phenylalanine, TMS ester 0.85 ⬇ * 
Glutamate, N-(TMS)-, bis (TMS) ester 0.79 ⬇ 
Glycine, N-(TMS)-, TMS ester 0.62 ⬇ 
L-alanine, N-(TMS)-, TMS ester 0.89 ⬇ 
L-Isoleucine,N-(TMS)-, TMS ester 0.68 ⬇ * 
Serine, bis (TMS) 0.92 ⬇ * 
Serine, N,O-bis (TMS)-TMS ester 0.58 ⬇ * 
Unidentified amino acid_1274_16.67 0.49 ⬇ * 
Unidentified amino acid_1305_17.43 0.69 ⬇ * 
Unidentified amino acid_1419_20.31 0.93 ⬇ 
Carbohydrates 
Mannose,2,3,4,5,6-pentakis-O-(TMS) 0.67 ⬇ * 
Unidentified carbohydrate_1879_29.85 0.79 ⬇ 
Unidentified carbohydrate_1907_30.39 0.95 ⬇ * 
Unidentified carbohydrate_2680_41.98 0.86 ⬇ 
Unidentified carbohydrate_2697_42.21 0.87 ⬇ 
Fatty Acids 
Decanoic acid, 1TMS_1459_21.39 0.92 ⬇ 
Hexadecanoic acid, TMS ester 0.97 ⬇ 
Nonanoic acid, TMS ester 0.91 ⬇ 
Stearic acid, 1TMS_2244_35.96 0.97 ⬇ * 
Others/Unknowns 
1,2,3-Propanetricarboxylic acid, 2-[(TMS)oxy]-, tris(TMS) ester 0.81 ⬇ 
2,3,4-trihydroxybutyric acid tetrakis (TMS) 1.04 ⬆ 
Cholesterol 1.07 ⬆ 
Unknown_1199_14.81 1.25 ⬆ 
Unknown_1249_16.04 2.61 ⬆ 
Unknown_1519_22.69 0.65 ⬇ * 
Unknown_1582_23.93 0.86 ⬇ 
Unknown_1589_24.07 1.49 ⬆ 
Unknown_1667_25.61 0.93 ⬇ 
Unknown_1723_26.74 1.04 ⬆ 
Unknown_1849_29.24 0.78 ⬇ * 
Unknown_1855_29.37 0.61 ⬇ 
Unknown_1920_30.60 0.88 ⬇ 
Unknown_1954_31.17 0.61 ⬇ 
Unknown_1962_31.31 1.65 ⬆ 
Unknown_2205_35.37 1.31 ⬆ 
Unknown_2226_35.65 1.05 ⬆ 
Urea 0.78 ⬇ 
Table 3.3. Fold changes seen in intracellular metabolites due to exposure to 1 µM malaoxon for 24 hours, against untreated 
cells. Green arrow indicates a fold increase and a red arrow indicates a fold decrease in the levels of metabolites between 
control and treatment at each time point. Black arrows also indicate a metabolite increase or decrease from 0. Equals sign 
indicates no change. n=10 for each sample group. Significant changes in the normalised peak area were calculated using the 
non-parametric Mann-Whitney U-test following log10 (x+1) transformation. *=p<0.05, **=p<0.005, ***=p<0.0005 
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B 
Figure 3.25. Principal component scores plot showing the variation in intracellular metabolites derived from SH-
SY5Y cells exposed to 10 µM RA for 120 hours and 1 µM malaoxon for 24 hours, or 10 µM RA for 120 hours. 
Grouping of treatment sample sets is represented by coloured ovals (blue=RA, red=RA+malaoxon). n=10 for 
each treatment group. B represents the corresponding loadings plot.  
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Metabolites RA v RA+M 
Amino acids 
2-pyrrolidone-5-carboxylic acid, TMS ester 1.04 ⬆ 
Glutamate, N-(TMS)-, bis (TMS) ester 1.09 ⬆ 
L-alanine, N-(TMS)-, TMS ester 1.45 ⬆ 
L-aspartic acid, bis (TMS) ester 1.14 ⬆ 
L-Isoleucine, N-(TMS)-, TMS ester 1.33 ⬆ 
L-threonine, O-(TMS)-, TMS ester 1.03 ⬆ 
L-Valine, N-(TMS)-, TMS ester 1.18 ⬆ 
N,O,O-Tris(TMS)-L-threonine 1.01⬆ 
N,O-bis (TMS)-L-phenylalanine 0.95 ⬇ 
Unidentified amino acid_1180_14.34 1.06 ⬆ 
Unidentified amino acid_1274_16.67 1.33 ⬆ 
Unidentified amino acid_1305_17.43 1.08 ⬆ 
Unidentified amino acid_1419_20.31 0.73 ⬇ 
Carbohydrates 
Unidentified carbohydrate_1879_29.85 0.74 ⬇ * 
Unidentified carbohydrate_2697_42.21 0.72 ⬇ 
Fatty Acids 
Dodecanoic acid, TMS ester 1.17 ⬆ 
Others/Unknowns 
1,2,3-Propanetricarboxylic acid, 2-
[(TMS)oxy]-, tris(TMS) ester 
2.04 ⬆ * 
Benzoic acid TMS ester 1.32 ⬆ 
Cholesterol 0.83 ⬇ 
Ethanamine, N-ethyl-N-[(ethylthio)methyl]- 0.94 ⬇ 
Unknown_1199_14.81 0.46 ⬇ 
Unknown_1519_22.69 1.04 ⬆ 
Unknown_1582_23.93 1.00 = 
Unknown_1589_24.07 0.67 ⬇ * 
Unknown_1758_27.43 1.62 ⬆ 
Unknown_1787_28.00 ⬆ ** 
Unknown_1849_29.24 0.72 ⬇ * 
Unknown_1855_29.37 1.56 ⬆ 
Unknown_1954_31.17 1.24 ⬆ 
Unknown_1962_31.31 0.76 ⬇ 
Urea 0.72 ⬇ 
Table 3.4. Fold changes seen in intracellular metabolites due to exposure to 10 µM RA for 120 hours and then 1 µM malaoxon 
for 24 hours, or 10 µM RA for 120 hours. Green arrow indicates a fold increase and a red arrow indicates a fold decrease in the 
levels of metabolites between control and treatment at each time point. Black arrows also indicate a metabolite increase or 
decrease from 0. Equals sign indicates no change. n=10 for each sample group. Significant changes in the normalised peak area 
were calculated using the non-parametric Mann-Whitney U-test following log10 (x+1) transformation. *=p<0.05, **=p<0.005, 
*=p<0.0005 
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Figure 3.26 shows the PCA scores plot for cell samples analysed following exposure to 
10 µM RA for 120 hours and 1 µM malaoxon for a further 24 hours, or 1 µM malaoxon 
for 24 hours, and the corresponding intracellular metabolite loadings plot. The results 
show grouping of control+malaoxon and RA+malaoxon cells. PC-4 explains 7% of the 
variance and is the PC most responsible for separation of the treatment groups. The 
loading plot (B) is a graphical representation of the individual metabolites most 
responsible for the variation seen in the PC scores plot. The information collected from 
the corresponding loadings plot produced a list of the intracellular metabolites that most 
contributed to the variance between the cells exposed to RA+malaoxon or malaoxon. 
This was analysed for any observable trends and significant changes. 
Table 3.5 illustrates the fold changes seen in the normalised peak area of intracellular 
metabolites due to exposure to 10 µM RA for 120 hours and 1 µM malaoxon for a 
further 24 hours, or 1 µM malaoxon for 24 hours, and which changes are significant. 
The data shows an overall increasing trend in the levels of amino acids and fatty acids, 
with the only significant change occurring in glycine (p<0.05). Changes in the levels of 
carbohydrates varied with increases in mannose and unidentified 
carbohydrate_1976_31.54, and a decrease in myo-inostiol. In addition, the 
other/unknown metabolites also varied with increases in 1,2,3-propanetricarboxylic acid 
and unknown_1787_28.00 and decreases in cholesterol, ethanamine and butanedioic 
acid. The metabolites listed in Table 3.5 were used to further investigate the differences 
observed by PCA comparing control+malaoxon and RA+malaoxon treated cells at 120 
hours. Details of that investigation are discussed in section 4.3.2.  
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Figure 3.26. Principal component scores plot showing the variation in intracellular metabolites derived from SH-
SY5Y cells exposed to 10 µM RA for 120 hours and 1 µM malaoxon for 24 hours, or 1 µM malaoxon for 24 hours. 
Grouping of treatment sample sets is represented by coloured ovals (blue=RA, red=RA+malaoxon). n=10 for each 
treatment group. B represents the corresponding loadings plot.  
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Metabolites C+M v RA+M 
Amino acids 
DL-Phenylalanine TMS ester 1.09 ⬆ 
Glutamate, N-(TMS)-, bis (TMS) ester 1.25 ⬆ 
Glycine, N, N-bis (TMS)-, TMS ester 1.08 ⬆ * 
L-alanine, N-(TMS)-, TMS ester 0.84 ⬇ 
L-aspartic acid, bis (TMS) ester 0.83 ⬇ 
L-Isoleucine, N-(TMS)-, TMS ester 1.45 ⬆ 
L-Valine, N-(TMS)-, TMS ester 1.16 ⬆ 
N,O,O-Tris (TMS)-L-Threonine 1.18 ⬆ 
N,O-bis (TMS)-L-phenylalanine 1.04 ⬆ 
Proline 1.04 ⬆ 
Tyrosine, O-TMS, TMS ester 1.05 ⬆ 
Unidentified amino acid_1274_16.67 1.58 ⬆ 
Unidentified amino acid_1419_20.31 0.92 ⬇ 
Unknown amino acid_1180_14.34 0.89 ⬇ 
Unknown amino acid_1305_17.43 1.34 ⬆ 
2-pyrrolidone-5-carboxylic acid, TMS ester 0.87 ⬇ 
Carbohydrates 
Myo-inositol,1,2,3,4,5,6-hexakis-O-(TMS) 0.55 ⬇ 
Mannose, 2,3,4,5,6-pentakis-O-(TMS) 1.33 ⬆ 
Unidentified carbohydrate_1879_29.85 0.86 ⬇ 
Unidentified carbohydrate_1976_31.54 1.07 ⬆ 
Unidentified carbohydrate_2680_41.98 0.96 ⬇ 
Unidentified carbohydrate_2697_42.21 0.76 ⬇ 
Fatty Acids 
Nonanoic acid, TMS ester 1.04 ⬆ 
Stearic acid, 1TMS_2244_35.96 1.04 ⬆ 
Others/Unknowns 
1,2,3-Propanetricarboxylic acid, 2-[(TMS)oxy]-, 
tris(TMS) ester, 
1.29 ⬆ 
1-O-tetradecylglycerol, bis (TMS) ether ⬆ ** 
2,3,4-trihydroxybutyric acid tetrakis (TMS) 0.29 ⬇ * 
Butanedioic acid, [(TMS)oxy]-,bis(TMS) ester 0.71 ⬇  ** 
Cholesterol 0.71 ⬇ 
Ethanamine, N-ethyl-N-[(ethylthio)methyl]- 0.80 ⬇ 
Unknown_1137_13.29 1.07 ⬆ 
Unknown_1199_14.81 0.38 ⬇ * 
Unknown_1249_16.04 0.34 ⬇ 
Unknown_1519_22.69 0.97 ⬇ 
A B 
Table 3.5. Fold changes seen in intracellular metabolites due to exposure to 10 µM RA for 120 hours and then 1 µM malaoxon 
for 24 hours, or 1 µM malaoxon for 24 hours. Green arrow indicates a fold increase and a red arrow indicates a fold decrease in 
the levels of metabolites between control and treatment at each time point. Black arrows also indicate a metabolite increase or 
decrease from 0. Equals sign indicates no change. n=10 for each sample group. Significant changes in the normalised peak area 
were calculated using the non-parametric Mann-Whitney U-test following log10 (x+1) transformation. *=p<0.05, **=p<0.005, 
*=p<0.0005. 
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Unknown_1589_24.07 0.62 ⬇ 
Unknown_1667_25.61 0.84 ⬇ 
Unknown_1723_26.74 0.75 ⬇ * 
Unknown_1758_27.43 7.46 ⬆ * 
Unknown_1787_28.00 2.21 ⬆ * 
Unknown_1849_29.24 0.94 ⬇ 
Unknown_1855_29.37 1.73 ⬆ 
Unknown_1920_30.60 0.53 ⬇ 
Unknown_1954_31.17 1.56 ⬆ 
Unknown_1962_31.31 0.72 ⬇ 
Unknown_2205_35.37 0.61 ⬇ ** 
Unknown_2226_35.65 0.83 ⬇ 
Urea 0.73 ⬇ 
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4. Discussion 
4.1 Optimisation of differentiation conditions 
Optimisation studies were used to determine the seeding density and concentration of 
retinoic acid (RA) required to successfully differentiate SH-SY5Y neuroblastoma cells. 
This was necessary as there is no definitive set of conditions (concentration and 
duration) stated for RA-induced differentiation of SH-SY5Y neuroblastoma cells in the 
literature. It was anticipated that by testing the effect of different densities and 
concentrations, optimal conditions could be identified that would successfully 
differentiate the cells using RA for metabolomic analysis. 
4.1.1 Seeding density 
SH-SY5Y neuroblastoma cells were seeded as a ratio of the proportion of flask volume 
used to seed one plate; 1:2, 1:4 and 1:6, and the treatment cells exposed to 10 µM RA. 
This initial concentration was chosen as it has been widely used to differentiate cells in 
previous studies (Agholme et al. 2010, Feng and Porter 1999, Miloso et al. 2004) (see 
Table 1.1). The cells were sampled every 24 hours for a total of 144 hours by 
photographing and counting.  
The results showed that by seeding at 1:2, cells treated with RA showed no strong 
increasing or decreasing trend in average cell count or as a percentage of the control 
(Figure 3.2). This indicates that RA-induced growth inhibition does not appear to be 
occurring. There was evidence of morphological differentiation in the cell photographs 
(Figure 3.1), meaning that the seeding density may have affected the extent of 
differentiation. The seeding density may have been too high for RA to have its full 
effect on growth inhibition, potentially due to a lack of nutrients which could affect the 
biochemical process of differentiation. At sufficient densities, cells can use up nutrients 
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in the media and enter the plateau phase where they stop cycling (Darzynkiewicz et al. 
2004). This may have occurred by 144 hours when there was a significant difference 
between control and treatment average cell count, as well as a decrease in actual counts 
for both. This may indicate that the nutrients had been exhausted, thereby affecting the 
total cell count and obscuring any trend that occurred due to differentiation 
(Darzynkiewicz et al. 2004). High seeding density may also have reduced the contact 
that RA had with the cells, as they would not all have been equally exposed, thereby 
affecting overall differentiation.  
By seeding at either 1:4 or 1:6, the RA-treated cells showed a stabilisation in average 
cell count and a decreasing trend as a percentage of the control. By 96-120 hours after 
the addition of RA, the average cell count had stabilised, probably due to 
differentiation-induced growth inhibition. The morphology of the cells illustrated the 
development of longer neurites and elongated cell shape commonly associated with a 
differentiated phenotype (Figure 3.1). Feng and Porter (1999) found that morphological 
changes could first be seen from 24-48 hours after exposure to RA. Based on the data 
from this optimisation study, and from the literature, the cells were likely partly or fully 
differentiated by 96-120 hours. 
The cells in 1:4 and 1:6 may have been seeded at a sufficiently low density to facilitate 
the differentiation process induced by RA. This may have also meant that nutrients in 
the media were not exhausted and RA would have been in approximately equal contact 
with the cells. The data suggests that changes in cell proliferation that were observed 
were likely due to the biochemical process of differentiation and not because cells had 
entered the plateau phase (Darzynkiewicz et al. 2004).  
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Although both densities did show the same pattern and trend in stabilisation of cell 
count and morphological change, a density of 1:4 produced a higher amount of cellular 
material, as measured by cell count. This is an important consideration as 1-2 x 10
6
 
cells/well is ideal for reproducible metabolomic analysis (Hollenbaugh et al. 2011, 
Sapcariu et al. 2014). In terms of actual cell number, the 1:4 seeding density equated to 
1.78 x 10
5
 cells/mL, which is comparable to other differentiation studies who seeded at 
2 x 10
5
 cells/mL (Agholme et al. 2010, Cheung et al. 2009, Wenker et al. 2010), 
although there have been other studies that used lower seeding densities of ~1x10
5
 
cells/mL (Feng and Porter 1999, Tieu et al. 1999). This is at least partly supported by 
our data, which suggests that using a lower seeding density for differentiation analysis 
can be just as effective as 1:4, but for use in metabolomic analysis, the amount of 
cellular material must be considered. Therefore the choice was made to use a 1:4 
seeding density for further analysis.  
Further studies of differentiation conditions should involve testing a wider range of 
seeding densities and therefore amounts of cellular material on the GC-MS 
instrumentation to determine the optimal loading for metabolomic analysis. This 
optimisation study determined that a 1:4 seeding density was adequate to produce RA-
differentiated SH-SY5Y neuroblastoma cells in a sufficient amount for metabolomic 
analysis.  
4.1.2 Retinoic acid concentration 
4.1.2.1 Lower concentrations (1 and 5 µM) 
SH-SY5Y neuroblastoma cells were seeded 1:4 based on the results of the previous 
optimisation experiment. Treatment cells were exposed to RA at concentrations of 1, 5, 
10 and 20 µM. These concentrations were selected as they span the range used in other 
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differentiation studies (Table 1.1). Cells were sampled every 24 hours for a total of 144 
hours by photographing and counting. 
The data showed that treating the cells with a concentration of either 1 or 5 µM RA, in 
comparison to the control, did not cause the expected decreasing or stabilising trend in 
cell count and therefore growth inhibition associated with differentiation (Figures 3.6 
and 3.7). The average cell count only started decreasing from 96 hours, and as a 
percentage of the control, there was not a consistent decreasing trend. It should be noted 
that the control for this experiment did show an unexpected decrease in average cell 
count at 120 hours. As the control cells had not been treated and would therefore not be 
affected by differentiation, growth was not expected to decrease and these samples 
should have had a higher cell count than the treatment cells. This may be an unexpected 
effect of the cells being left in the media for an extended period of time, which would 
affect levels of nutrients and pH. This was not observed for the same seeding density in 
the first optimisation experiment, potentially due to variation in the population of the 
cultured cells between experiments. If the control had been higher, there may have been 
a significant difference for the last three time points instead of just at 96 and 144 hours, 
and therefore a more obvious trend between control and treatment may have been 
present.  
Other studies have used 1 or 5 µM to successfully differentiate cells including Lasorella 
et al. (1995), Singh et al. (2003) and Korecka et al. (2013), suggesting that these 
concentrations are sufficient for differentiation, but it has been noted that they may 
induce differentiation to a lesser extent. The cell photographs depict the expected 
change in morphology associated with differentiation, therefore further studies are 
required, with more replicates, to definitively determine the difference between control 
and treatment at these concentrations. This may also help identify an appropriate 
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method to supplement the cells if nutrients in the media were being depleted too 
quickly. Regular changing of the media could be considered, but was not implemented 
here due to the fragile nature of the cells, particularly once treated (Langlois and Duval 
1997). Based on the data from this study and the literature, it is possible to differentiate 
SH-SY5Y cells at these concentrations of RA. However, the higher concentrations 
tested gave clearer results in terms of growth inhibition; and therefore concentrations of 
1 and 5 µM were not used for further analysis. 
4.1.2.2 Higher concentrations (10 and 20 µM) 
The data showed that treating the cells with a concentration of either 10 or 20 µM RA 
produced a stronger trend in cellular differentiation in terms of the average cell count 
and as a percentage of the control, as seen in Figures 3.8 and 3.9. From 48 hours, the 
average cell count in both concentrations followed a decreasing/stabilising trend, whilst 
as a percentage of the control showed a decreasing trend with time. As mentioned 
above, if the control had been at the expected, higher cell count, it is likely that the last 
three time points would have been significantly different from the control, but the 
current data indicates that in both concentrations only 96 and 144 hours were 
significant. At both concentrations, it could be seen that, by 96 hours post RA exposure, 
the average cell count had significantly decreased and stabilised, probably due to 
differentiation-induced growth inhibition, while the photographs showed extension of 
neurites and elongated cell bodies at 96 and 144 hours (Figure 3.5). As these are key 
factors in assessing differentiation, it can be said that by 96 hours, based on morphology 
and cell count data, the cells were likely partly or fully differentiated.  
Based on the data, either 10 or 20 µM could have been used in further analysis to 
differentiate the cells. There have been studies using 20 µM, including Tieu et al. 
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(1999), but 10 µM is the concentration most commonly used to differentiate SH-SY5Y 
cells (Ammer and Schulz 1994, Cheung et al. 2009, Feng and Porter 1999, Miloso et al. 
2004, Yu et al. 2003). At later time points, which are the focus for further analysis, the 
average cell count was higher at 10 µM; therefore there was more cellular material 
which, as previously mentioned, is important for metabolomic analysis. Also, data from 
10 µM would be more comparable to other studies, and therefore was chosen for future 
analysis.  
Further studies should include repeating the experiment with greater replication, as 
previously mentioned, to better determine the behaviour of the control, and the overall 
trend. It could also include more extensive optimisation where the different 
concentrations could be tested on different seeding densities to see what effect this has, 
and better determine an optimal concentration and seeding density. This would work 
towards achieving a comprehensive set of conditions that could be used as a standard 
for RA-induced differentiation on SH-SY5Y cells. The lack of a standard differentiation 
protocol in the literature suggests that optimal conditions have been difficult to 
determine and highlights the fact that robust experiment design and protocols are crucial 
within any given study.  
This optimisation study determined that 10 µM RA was sufficient for differentiation 
and metabolomic analysis, at a seeding density of 1:4. This provided us with sufficiently 
optimised conditions to differentiate the SH-SY5Y human neuroblastoma cell line with 
RA for the remaining experiments of this study.  
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4.2 Analysis of differentiation in 6- and 24-well plates 
4.2.1 Plate type 
The optimised differentiation parameters were examined in 6- and 24-well plates as, in 
this lab, SH-SY5Y cells have not been routinely cultured for this length of time, and 
some variation was observed in the behaviour of cells in 6-well plates during earlier 
experimentation. A comparison was made with 24-well plates, which were used for the 
optimisation studies, in order to determine the effectiveness of the differentiation 
process in each plate type, and whether metabolomic data was comparable between 
plate types. Metabolite data from this study was also used to determine which day 
would be the focus of further differentiation analysis. Identifying an optimal point at 
which to study the biochemical changes due to differentiation would add to the 
knowledge available in the literature in relation to studying the biochemical effects of 
RA-induced differentiation. 
SH-SY5Y neuroblastoma cells were seeded 1:4 in 6- and 24-well plates and were 
exposed to 10 µM RA. Cells were sampled every 24 hours for a total of 144 hours 
followed by photographing, counting and harvesting for metabolomic analysis. Samples 
were subsequently extracted, derivatised and analysed by GC-MS. The data showed that 
in 6-well plates there was a decreasing trend in cell count compared to the control, and 
also a decreasing trend as a percentage of the control (Figure 3.11). The optimised 
combination of parameters outlined earlier appeared to successfully differentiate the 
cells, as there was growth inhibition and the expected morphology, as seen in Figure 
3.10. The combination of parameters was also used by Cheung et al. (2009) and Wenker 
et al. (2010) to successfully differentiate SH-SY5Y neuroblastoma cells.  
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In 24-well plates, using the same parameters, there was a decreasing and stabilising 
trend in both average cell count and percentage of control (Figure 3.12). Growth 
inhibition was occurring and the expected morphology was apparent, as seen in the 6-
well plates. This was expected as the plate type should not adversely affect the 
differentiation process, although the limited number of counts meant that significance 
testing could not be carried out. It would be beneficial to repeat this study with a larger 
number of replicates.  
Principal component analysis (PCA) demonstrated that when all replicates from each 
time point, for each plate type, were modelled together, grouping was based on the 
treatment and not on the plate type. The observed grouping indicated minimal variation 
within control and within treatment groups across the plate types. This indicates that 
while exposure to RA caused biochemical changes to the cells as reflected in the cell 
count and morphology data, this was irrespective of the plate type in which the 
experiment was carried out. From this data, it is apparent that a change had occurred in 
the metabolite profile following RA-induced differentiation of SH-SY5Y 
neuroblastoma cells. From this part of the experiment, we can conclude that 
differentiation appears to have occurred comparably in both plate types. Given that 
metabolomic protocols had previously been optimised for 6-well plates, these were 
selected for further differentiation analysis (Wenner et al. 2015).  
Further testing should involve a larger number of counts and replicates as only one 
count/plate was carried out for 6-well plates and two counts/plate for 24-well plates, due 
to the amount of material required for metabolomic analysis. This would give a greater 
comparison between the two plate types in terms of differences in cell number. A 
greater number of replicates for metabolomic analysis (n=3 for this experiment) would 
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help in identifying which aspects of the observed variation were due to the 
differentiation process. 
4.2.2 Duration of exposure   
This experiment was also carried out to determine which time point would be the focus 
of the subsequent experiments. The goal was to determine by which point the majority 
of biochemical changes had occurred, in comparison with the morphological and cell 
count data, which suggested that the cells were likely differentiated by 96-120 hours. 
This would help determine an optimal point at which to study the biochemical changes 
due to differentiation.  
Examination of the combined PCA (Figure 3.14) that modelled all replicates for control 
and RA in 6-well plates over each time point showed clear clustering of the treatment 
groups from 72 hours onwards with separation of RA-treated cells and untreated cells, 
indicating a clear difference in metabolite profiles. The RA-treated 24- and 48-hour 
groups clustered with control cells, suggesting similarity of metabolite profiles, 
demonstrating limited biochemical change occurring at 24 and 48 hours after the 
addition of RA. This could also be seen from the morphology and cell count data 
produced in this study as significant differences to the control, stabilisation of growth 
inhibition and morphological changes occurred from 72-96 hours onwards. Aside from 
24 hours, where clear clustering could not be seen, modelling of control and RA-treated 
replicates at each time point showed a trend in separation of control and treatment and 
therefore some level of biochemical difference (Figures 3.15-3.17). The most distinct 
separation and therefore difference in metabolite profile was observed at 120 hours after 
addition of RA (Figure 3.17).  
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The intracellular metabolites that most contributed to the variance between groups were 
extracted from the loadings data for each time point and compiled, from which fold 
changes and p-values were calculated. Examination of Table 3.1 indicates variation in 
the levels of amino acids and other/unknown metabolites with most significant changes 
occurring at 120 and 144 hours after RA exposure. Carbohydrates and fatty acids all 
showed some increase across the time points, particularly at 96, 120 and 144 hours, 
where many of the metabolites displayed significant increases. This trend was seen 
across all classes of metabolite where the majority of significant differences to the 
control occurred at 120 hours.  
A duration of 144 hours is commonly used for differentiation analysis as seen in studies 
by Ammer and Schulz (1994), Lasorella et al. (1995), Sharma et al. (1999), Tieu et al. 
(1999) and Yu et al. (2003), and numerous significant changes were observed in this 
data at that time point. Although, data from both this experiment and initial optimisation 
studies showed a decrease in cell count at 144 hours, along with the presence of dead 
cells. It was not clear if the decrease in cell count was due to differentiation or due to a 
depletion of nutrients in the media, and as discussed earlier, having sufficient cellular 
material is crucial for metabolomic analysis. Based on this data, along with the 
clustering observed from PCA, and the cell count and morphological changes seen in 
the data, a time point of 120 hours was chosen for further analysis.  
4.2.3 Biochemical changes associated with differentiation 
In order to investigate the biochemical changes that may contribute to the effects of RA 
exposure on cellular metabolism, a range of metabolites with significant differences at 
120 hours were explored further. Four metabolites each from the carbohydrate and fatty 
acid classes were investigated for changes in average peak area compared to the control 
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across all time points. The carbohydrate and fatty acid metabolites in the replicates 
treated with RA showed an increasing trend over the time points, with all metabolites 
having a significant increase from the control at 120 and 144 hours. The four fatty acids 
showed a significant increase from the control at 120 hours, with hexadecanoic acid and 
stearic acid also having significant increases at 96 and 144 hours.  
An increase in the levels of carbohydrate and fatty acid metabolites suggests a change in 
energy metabolism due to RA exposure. This change in metabolism caused an 
accumulation of these metabolites including D-fructose, and the straight, medium and 
long chain saturated fatty acids. The changes subsequently indicate a decrease in 
carbohydrate catabolism through the pathways of glycolysis, TCA cycle and the 
electron transport chain, as well as a decrease in β-oxidation of fatty acids (Schönfeld 
and Reiser 2013).  
A decrease in the need for energy consumption is expected during the process of RA 
differentiation. This has been discussed in a number of studies that observed growth 
inhibition as a consequence of differentiation that involves cell cycle arrest in the G1-
phase, withdrawing from the cell cycle, and inhibiting DNA synthesis (Agholme et al. 
2010, Constantinescu et al. 2007, Tucholski et al. 2001, Xun et al. 2012).  
The dependence of neuronal cells on fatty acids for energy production is more reserved 
in comparison to glucose which is the main oxidative fuel in the brain (Ebert et al. 
2003, Schönfeld and Reiser 2013). It has been shown that oxidation of fatty acids can 
contribute up to approximately 20% of the energy requirement of the brain (Ebert et al. 
2003, Panov et al. 2014, Schönfeld and Reiser 2013), while glucose is the main 
imperative energy substrate (Bélanger et al.). The reasons for this difference are due to 
the nature of the β-oxidation process. Neuronal cells can achieve high levels of rapid 
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ATP production and therefore use of glucose is favoured due to the faster rate at which 
catabolism occurs in comparison to β-oxidation (Schönfeld and Reiser 2013). A second 
reason is in relation to oxidative stress; β-oxidation is selected against due to its 
production of reactive oxygen species (ROS), as neuronal cells have a high 
susceptibility to oxidative stress (Schönfeld and Reiser 2013). The presence of fatty 
acids indicates some use of these pathways by SH-SY5Y neuronal cells and may be 
affected by changes in carbohydrate metabolism following differentiation, and possibly 
by differences between in vitro and in vivo systems.  
A limitation to interpretation of this data is the lack of consensus as to what constitutes 
a differentiated cell. Not all studies of the effects of RA-induced differentiation have 
discussed the change in growth, instead focusing on changes in neurite outgrowth. Data 
from this study shows that change in morphology, growth and biochemistry should all 
be considered in determination of when cellular differentiation has occurred. A 
subsequent study could focus more on the biochemical process of differentiation and the 
change in metabolites over each of the 24-hour time points, more definitively 
determining the point of differentiation. Supplementation or changing of the media 
should also be considered in order to differentiate to 144 hours and be comparable with 
some other studies. Producing a preliminary set of criteria that can define RA-
differentiated cells is an important outcome for this study and should be considered for 
future studies in order to determine when a SH-SY5Y cell has become fully 
differentiated. Our suggested criteria are outlined in section 4.3.1.2. 
This initial investigation has indicated that 120 hours was an optimum point where a 
range of changes associated with differentiation appeared to have occurred, and has 
identified some of the metabolites and metabolite classes that may be important for 
studying RA-induced differentiation. Analysis indicated that significant changes in 
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energy metabolism occurred due to the biochemical changes associated with RA-
induced differentiation. Collectively these changes warrant further analysis of RA-
induced differentiation.  
4.3 Differentiation analysis and malaoxon exposure 
The final experiment of this study considered several aspects: the biochemical response 
of RA-induced differentiation; the effect of malaoxon on undifferentiated and 
differentiated SH-SY5Y neuroblastoma cells; and whether differentiated cells are more 
appropriate for future toxicology research. SH-SY5Y neuroblastoma cells were seeded 
at a density of 1:4 and exposed to 10 µM RA for 120 hours. At 96 hours, half of the 
control and treatment replicates were exposed to 1 µM malaoxon for a further 24 hours. 
Immediately before harvesting, photographs, cell count and cell viability were 
determined to document the morphological changes resulting from RA and malaoxon 
exposure (Figure 3.20). Subsequently, the cells were harvested, extracted, derivatised 
and analysed by GC-MS.  
4.3.1 Control and RA-differentiated 
Comparison of undifferentiated and RA-differentiated cells showed that following 
exposure of cells to 10 µM RA, there was a non-significant decrease in average cell 
count compared to the control. Changes in morphology were comparable to previous 
experiments in this study using the same parameters, and to the literature (Agholme et 
al. 2010, Cheung et al. 2009, Tieu et al. 1999). There was some variation in the cell 
count compared to the previous experiments. This may be accounted for by variation in 
passage number between experiments as the cells may not be uniform over their 
lifespan. This was unavoidable in this study due to time constraints, but may be 
important and has not, to date, been considered in a metabolomics study. Additionally, a 
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fault in the incubator in relation to CO2 levels was identified and rectified between 
experiments, potentially affecting growth conditions. Repeating this portion of the 
experiment with the same or similar passage number as previous experiments is 
recommended to increase comparability. Despite the variation, the change in cell count 
and morphology reflected the changes expected with differentiation and, in correlation 
with previous experiments, suggests that the cells have been differentiated after 120 
hours exposure to RA.  
Examination of both the combined PCA (Figure 3.22) and control vs. RA-treatment 
PCA (Figure 3.23) shows clear grouping and separation of the replicates for each 
sample type. This indicates that there was a difference in the metabolite profile and 
therefore biochemical change due to RA exposure. The variance explained by the PCA 
was quite low (between 3 and 15%). This indicates that there were other factors 
contributing to the variation observed within the data. This may be due to the 
instrumental analysis or sample preparation, and highlights the need for robust 
experimental design when studying potentially subtle biochemical changes. The PCA 
plots do however indicate that multivariate analysis allows the data to be modelled 
based on differences between control and treatment and not other factors. 
4.3.1.1 Amino acids 
The data showed an overall decreasing trend in the levels of all amino acids compared 
to the control at 120 hours. A decrease suggests that there had been an increase in the 
metabolism of these amino acids. Amino acids can be utilised for synthesis of proteins, 
RNA and DNA, cell signalling, growth and as an energy substrate (Wu 2010). The 
amino acids detected in this experiment may be participating in these roles, as RA-
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induced differentiation requires a range of cellular and biochemical changes, including 
synthesis of new proteins, DNA and RNA, and changes in growth and cell signalling.  
A key change in differentiation is the outgrowth of neurites, which is seen as a key 
indicator that a cell has become differentiated. This requires activity of a number of 
proteins and enzymes including protein kinase C (PKC), phosphoinositide-3-kinase 
(PI3K), JNK, cyclin-dependent kinase 5 (CDK-5) and the neurofilament (NF) proteins, 
all of which either play a direct role in neurite outgrowth or activate proteins required 
for the process (Miloso et al. 2004, Pan et al. 2005, Sharma et al. 1999, Singh et al. 
2003, Yu et al. 2003). It also involves growth associated protein-43 (GAP-43), a 
neuron-specific protein present in growth cones that is necessary for guiding the 
outgrowth of the neurite (Singh et al. 2003). A second key change is rearrangement of 
the cytoskeleton, which requires synthesis of numerous proteins. These include the NF 
proteins, which are part of the major fibrillary elements of the cytoskeleton itself and 
RhoA which is also required for cytoskeletal rearrangements (Miloso et al. 2004, Pan et 
al. 2005, Sharma et al. 1999, Singh et al. 2003). Amino acids may be required in these 
processes as they play a role in growth, synthesis of new proteins and signalling 
changes. 
Other changes required during RA-induced differentiation include synthesis of the 
apoptotic regulator protein Bcl-2, which has a role in maintaining neuronal survival, as 
well as ERK1/ERK2 (Lasorella et al. 1995, Miloso et al. 2004). ERK1/ERK2 also 
phosphorylates signal transduction proteins and certain transcription factors, thereby 
regulating gene expression (Miloso et al. 2004). Increases are also seen in the level of 
tissue transglutaminase (TGase), which plays a role in signal transduction pathways, has 
transamidation activity, and is a regulator of apoptosis and MAP kinase activation 
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(Tucholski et al. 2001). All of these changes are stimulated due to RA-induced 
differentiation and suggest the need for amino acids. 
Although RA-induced differentiation is known to induce inhibition of cell proliferation 
and decrease DNA synthesis and therefore cause a decrease in the energy requirements 
of the cell, amino acids may have been metabolised to produce energy via either 
pyruvate or TCA cycle intermediates (Agholme et al. 2010, Constantinescu et al. 2007, 
Tucholski et al. 2001, Wu 2010, Xun et al. 2012) (KEGG, 
http://www.genome.jp/kegg/). Amino acids could be a potential source of energy for the 
processes discussed, including synthesis and neurite outgrowth.  
The only two amino acids to have significantly decreased were glycine and serine. 
Serine plays a crucial role in many cellular processes including protein synthesis, and 
ceramide production (de Koning et al. 2003, Simo S. Oja et al. 2007). The metabolism 
of serine in order to carry out nucleotide synthesis is catalysed by serine 
hydroxymethyltransferase (SHMT) which reversibly converts serine to glycine (de 
Koning et al. 2003, Simo S. Oja et al. 2007). This is a key source of single-carbon 
groups that provide formyl groups for purine synthesis and methyl groups for 
pyrimidine synthesis (de Koning et al. 2003, Simo S. Oja et al. 2007). Ceramide is a 
component of sphingomyelin and plays an important role in intracellular signalling in 
relation to regulation of differentiation, senescence and apoptosis (de Koning et al. 
2003, Tanaka et al. 2012). Tanaka et al. (2012) demonstrated that RA-induced 
differentiation caused an accumulation in ceramide levels, while de Koning et al. (2003) 
discussed that if synthesis of ceramide was inhibited in cerebellar purkinje cells, it 
caused impairment in neuronal survival and increased apoptosis. Both of these studies 
support the conversion of serine into ceramide, potentially explaining the decrease in 
serine levels observed following exposure to RA. Glycine is involved in protein 
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metabolism, DNA and energy production, and is both an inhibitory and excitatory 
neurotransmitter in the nervous system (Betz and Harvey 2001, Simo S. Oja et al. 
2007)(www.hmdb.ca).  
If amino acids were being used in the pathways suggested, it may be expected that 
biosynthesis would occur to replace the amino acids utilised. But if the process and 
associated changes have already occurred and the amino acids have been used in these 
changes, biosynthesis may no longer be required. A consideration in interpreting the 
data from this study is that these are snapshots of specific time points, rather than 
observing the specific processes in action.  
4.3.1.2 Carbohydrates and fatty acids 
In terms of the fold changes observed in the carbohydrate and fatty acid metabolites, the 
majority of those that increased in the previous data (Section 4.2.3) were not identified 
by PCA as making a major contribution to the variance between the control and 
treatment in this experiment. However, inspection of the data showed that there were 
similar trends in this experiment. D-fructose, unidentified carbohydrates 1 and 4, 
hexadecanoic acid and stearic acid all increased compared to the control, and decanoic 
acid and unidentified fatty acid 1 decreased. The increased levels and possible 
accumulation of these metabolites indicates a decrease in the use of energy from 
carbohydrate and fatty acid precursors, reflecting the decreased need for energy as a 
result of RA-induced differentiation as discussed in section 4.2.3. For example, 
increased levels of D-fructose and mannose suggest that these metabolites were not 
being utilised in their respective metabolic pathways, such as glycolysis (KEGG, 
http://www.genome.jp/kegg/). The data also suggests that fatty acids may be used for 
biosynthesis over catabolism via β-oxidation, which fits with the observation that, in 
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neurons, glucose is favoured for catabolism over fatty acids (Ebert et al. 2003, 
Schönfeld and Reiser 2013). While energy generation associated with growth may have 
decreased, energy was still required for other cellular processes previously discussed 
including protein synthesis and neurite outgrowth.  
While the trend in these metabolites was similar to the earlier experiment, variation 
exists when comparing the data due to differences in experimental design. The second 
experiment had more replicates (n = 10 as compared to n = 3), which improved 
reproducibility and decreased variation as reflected in the relative standard deviation 
(RSD) values. The first study had an average RSD of 104%, compared to 85% for the 
second study. These values are high, but are comparable with that seen in other 
untargeted studies in this laboratory. Variation may also be accounted for by the 
difference in passage number between each analysis, as discussed earlier. 
Focusing on the metabolites identified as important from this experiment by PCA, a 
decrease was seen in myo-inositol, which plays an important role in the production of 
the second messenger phosphatidylinositol-4,5-bisphosphate (PIP2). In eukaryotes myo-
inositol is a precursor in the production of phosphatidylinositol (PI)  (Gonzalez-Salgado 
et al. 2012). This process involves the PI cycle in which the precursor myo-inositol, 
through PI, produces PIP2 and subsequently the second messengers 1,2-diacylglycerol 
(DAG) and inositol-1,4,5-triphosphate (IP3) (Kim et al. 2005, Shulga et al. 2010). This 
activates protein kinase C (PKC) and mobilises intracellular calcium, which initiates 
various signalling cascades (Kim et al. 2005, Shulga et al. 2010). IP3 can be synthesised 
to regenerate the levels of myo-inositol (Kim et al. 2005), while from DAG, PI can be 
synthesized to produce PIP2. This data suggests that RA-induced changes in myo-
inositol likely play an important role in the stimulation of second messengers that 
contribute to the process of differentiation. Miloso (2004) suggests that PKC may 
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potentially be part of the cascade responsible for activation of ERK1/ERK2, which is 
involved in activation of gene and neurite outgrowth (Figure 1.9).  
Activation of PI3K can occur through RA differentiation (Lopez-Carballo et al. 2002). 
The PIP2 second messenger can be converted into phosphatidylinositol-3,4,5-
trisphosphate (PIP3) through PI3K, subsequently causing activation of the downstream 
target Akt (Hemmings and Restuccia 2012). Akt is a serine/threonine protein kinase that 
is responsible for a broad range of downstream effects including mediating the 
processes of metabolism, proliferation, protein synthesis, and apoptosis through 
inactivation of pro-apoptotic proteins and regulation of survival genes (Hemmings and 
Restuccia 2012, Vara et al. 2004). Akt also activates CDK’s of which CDK5 plays a 
role in neurite outgrowth (Sharma et al. 1999). PI3K has also shown to be important in 
activation of Rho GTPases which play a part in both cell survival and cytoskeletal 
rearrangements (Korecka et al. 2013, Pan et al. 2005). The effects of RA-induced 
differentiation have been demonstrated to change the survivability of the cell, which 
may partly be due to this pathway, in conjunction with the effects of proteins and 
enzymes including Bcl-2, ERK1/ERK2 (Cheung et al. 2009, Tieu et al. 1999)  
Levels of succinic acid, a TCA cycle intermediate, also changed in response to RA 
exposure.  In situations where glucose is unavailable, amino acids can be metabolised to 
either pyruvate or TCA cycle intermediates to produce energy. Increases in succinic 
acid may be due to isoleucine, valine or threonine being converted into succinyl CoA, 
or proline being converted first into glutamate and then α-ketoglutarate (Wu 2010). This 
may account for the decreases seen in amino acids, as the data suggests that 
carbohydrates like D-fructose were not being utilised, and therefore the cell may have 
been utilising other energy sources. It has been found that differentiated cells depend 
more on oxidative phosphorylation for energy, whereas undifferentiated cell depend 
116 
 
more on glycolysis (Schneider et al. 2011, Xun et al. 2012). This may further indicate 
reliance in RA-differentiated cells on utilisation of energy sources such as amino acids, 
as they are metabolised to pyruvate or TCA cycle intermediates, thereby not utilising 
the glycolytic pathway. No other TCA intermediates were identified as important from 
the data, which would be expected with a decrease in succinic acid. This may be due to 
the analytical method, as ‘activated’ energy metabolites may be short-lived or unstable, 
and highlights the need for broad coverage of the metabolome.  
Analysis of the metabolic changes associated with RA-induced differentiation is novel, 
as studies investigating this change have used techniques that have focused on upstream 
changes associated with genes, proteins and enzymes. Metabolomics, on the other hand, 
looks at downstream metabolite changes that are closer to the phenotype and therefore 
is most reflective of what is occurring. The data from this part of the study has shown 
that SH-SY5Y neuroblastoma cells were morphologically and biochemically 
differentiated after 120 hours exposure to RA and these metabolite changes could be 
profiled using GC-MS metabolomic analysis. A metabolite profile for RA differentiated 
SH-SY5Y cells was produced and changes in biochemical pathways, which agree with 
the published literature, were identified (Figure 4.1). Continuation of this study should 
involve analysing the process of differentiation further at multiple time points, as 
opposed to a final time point when the cells are already differentiated; this study focuses 
on the end result not the changes at each stage of the process. This would involve 
evaluating the changes over time points, with a larger number of replicates as this would 
improve reproducibility. A potential consideration for future work in this area is the 
implementation of flux analysis which uses mathematical models to study the flow of 
metabolites in biochemical networks to understand how the flow of changes due to 
treatment e.g. exposure to RA (Orth et al. 2010).  
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4.3.1.3 Criteria for RA-induced differentiation 
An important outcome of this study was determining a set of criteria that could be used 
to successfully differentiate SH-SY5Y cells with RA including a series of optimisation 
experiments. This is valuable as there is currently no defined set of conditions that are 
routinely used in the literature in terms of concentration of RA and duration of 
exposure. Through this study we have shown that changes in morphology, growth and 
biochemistry are all important considerations. This preliminary data indicates that a 
differentiated cell can be morphologically identified by an outgrowth of neurites, the 
change from a rounded to an elongated cell type and the presence of more cell-cell 
connections. In terms of growth, RA-differentiation causes a slowing of the growth rate, 
such that 96-120 hours after exposure, cell numbers have stabilised. The morphological 
and growth changes were found to be reflected in the biochemistry as there was a 
decrease in metabolites associated with energy production, and an increase in 
metabolites associated with neurite outgrowth, cytoskeletal rearrangements, protein, 
RNA and DNA synthesis, cell signalling, and apoptosis and survival regulation. 
Through metabolomic analysis, we determined that the majority of significant changes 
in comparison to the control had occurred by 120 hours after RA exposure. We found 
that these results could be produced by seeding the cells at 1:4 in 6-well plates and 
exposing the cells to 10 µM RA for a period of 120 hours. Preliminary studies such as 
this are important for the development of robust methods and criteria to successfully 
differentiate cells. This information will aid in the design of future studies that would 
further analyse the differentiation process, and encompass more replicates and potential 
supplementation of the media, to ensure reproducibility. 
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4.3.2 Malaoxon exposure 
The results show that there was a non-significant increase in average cell count when 
comparing cells treated with malaoxon for both control and RA-treated (Figure 3.21). 
Exposure to malaoxon in both cases caused a non-significant decrease in average 
viability, although the average viability of RA-treated was higher than control. The 
morphology of control cells and RA-treated cells exposed to malaoxon was similar, but 
there were more dead cells in the control cell population, whilst RA-treated had fewer 
cells overall. The changes in cell viability and appearance reflect the fact that malaoxon 
caused a limited toxicological effect on SH-SY5Y, and that RA may have had a 
protective effect. Examination of the PCA’s (Figures 3.22, 3.24, 3.25, 3.26) shows a 
level of separation for control and RA-treated cells exposed to malaoxon with some 
overlap between the sample types. This indicates that there was a degree of similarity in 
metabolite profile between the treatment groups, but that there was a biochemical 
change due to malaoxon exposure.  
Overall viability remained relatively high at over 90%, comparable to Balbuena (2010), 
who saw 87% viability when using 1 µM malaoxon on SH-SY5Y cells. This data 
suggests that the toxic effect of this concentration of malaoxon was quite subtle, which 
was desired as we wanted to investigate biochemical effects rather than the cytotoxic 
response. A higher concentration would have produced a greater change in viability and 
more separation on the PCA, but this would have affected the viable volume of cells 
available for metabolomic analysis.  
The fold change table for control/malaoxon (Table 3.3) indicates that the important 
amino acid, carbohydrate and fatty acid metabolites had all decreased in comparison to 
the control, with multiple significant changes. The other/unknown metabolites had a 
variable response with an increase seen in cholesterol. The fold change table for RA-
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treated/malaoxon (Table 3.4) shows a mostly increasing trend in the important amino 
acid and fatty acid metabolites. Decreases were seen in the levels of carbohydrates and 
cholesterol.  
The fold change table comparing undifferentiated and RA differentiated cells exposed 
to malaoxon (Table 3.5) is comparable to RA-differentiated cells exposed to malaoxon 
(Table 3.4), as there was an increase in the majority of amino acids and fatty acids and 
decreases in the shared carbohydrates and cholesterol. There was also an increase in 
mannose and a decrease in myo-inositol, both of which were seen in RA-differentiated 
cells (Table 3.2), where myo-inositol was identified as important in the differentiation 
process. Comparing differentiation between the experiments of this study is difficult, as 
the cells treated with both RA and malaoxon, and malaoxon only, had malaoxon added 
at 96 hours and then harvested after 120 hours, whereas cells exposed to RA only were 
exposed uninterrupted for 120 hours. Malaoxon may therefore have affected the process 
of differentiation causing potential differences in these analyses. Overall, the cell count, 
viability, morphology and PCA data supports a difference in the biochemical change 
due to malaoxon exposure between undifferentiated and RA differentiated cells. 
4.3.2.1 Control/malaoxon 
A potential explanation for the change in amino acids in cells exposed to malaoxon may 
be excitotoxicity, which is a process whereby excessive stimulation of glutamate 
receptors causes a neurotoxic cellular response leading to injury and apoptosis and/or 
necrosis (see Figure 4.2 for proposed workflow) (Dong et al. 2009, Wang and Qin 
2010). The pesticide malaoxon inhibits acetylcholinesterase (AChE), resulting in ACh 
accumulation and subsequent overstimulation and excitation of neurons. Persistent 
activation by ACh may result in extracellular accumulation of glutamate, a major 
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excitatory neurotransmitter, and extended receptor activation, subsequent excitotoxicity, 
cell injury and death (Dong et al. 2009, Meldrum 2000). This may explain the change 
seen in glutamate levels with malaoxon exposure. The effects of glutamate-mediated 
excitation occur via activation of two types of receptor: ionotropic, ligand-gated ion 
channels which include NMDA, AMPA and kainate receptors; and metabotropic which 
are coupled to G proteins and modulate second messengers (Dong et al. 2009, Meldrum 
2000). NMDA receptor is key in this process and causes an increase in the level of 
intracellular calcium (Dong et al. 2009, Mark et al. 2001). The NMDA receptor requires 
glycine as a co-agonist, which may partly explain the decrease seen in glycine if it is 
required for action of the receptor (Mark et al. 2001). Activation of G proteins causes 
activation of signalling pathways through either cyclic adenosine monophosphate 
(cAMP) or the PI cycle that can cause mobilisation of calcium (Ca
2+
) stores (Dong et al. 
2009), resulting in an increase in intracellular Ca
2+
. 
An overload of intracellular Ca
2+
 due to the action of both ionotropic and metabotropic 
receptors is neurotoxic and affects homeostasis causing the activation of proteases, 
phospholipases, kinases, endonucleases, nitric oxide (NO) synthase, PKC, activation of 
pro-apoptotic proteins including cytochrome c, and oxidative stress that can stimulate 
free radical generation including reactive oxygen species (ROS) and reactive nitrogen 
species (RNS) (Dong et al. 2009, Grant et al. 2001, Mark et al. 2001, Skaper et al. 
2001). ROS can damage proteins and DNA, and cause lipid peroxidation that damages 
membrane lipids and therefore the cell membrane (Catalá 2009) (Wang and Qin 2010). 
Cholesterol is an important part of the cell membrane and levels were increased, 
suggesting that damage and breakdown of the cell membrane may be releasing 
cholesterol (Ong et al. 2010). It has been found that glutamate excitotoxicity can 
increase levels of cholesterol, cholesterol oxidation products produced from ROS, 
121 
 
cholesterol precursors and oxysterols (Ong et al. 2010). This may indicate a protective 
response due to differentiation as the level of cholesterol had decreased in the RA-
treated/malaoxon cells, which is in accordance with the decrease in cholesterol seen in 
RA-differentiated cells. NO, produced from NO synthase, cause’s overexpression of 
metalloproteinases that destroy the extracellular matrix of neuronal cells, therefore 
excitotoxicity may also be responsible for the detached cells observed with malaoxon 
treatment (Dong et al. 2009).  
Cellular damage and apoptosis from the malaoxon-induced excitotoxic process can also 
be due to activation of the JNK pathway and DNA binding activity of the NF-κB 
transcription factor (Dong et al. 2009, Grant et al. 2001, Skaper et al. 2001).Other 
signal transduction pathways that moderate the effects of excitotoxicity include the 
MAPK/ERK1/2 cascade, which has been found to be activated after stimulation of 
glutamate receptors (Grant et al. 2001, Wang and Qin 2010). Phosphorylation of the 
transcription factor cAMP response element binding protein (CREB) may be a 
downstream target of MAPK activation (Grant et al. 2001, Wang and Qin 2010). As 
further discussed in 4.3.2.2, these proteins, enzymes and transcription factors are also 
utilised in RA-differentiation. 
Under normal conditions, the mitochondria and cell membrane play a crucial role in 
maintenance of low cytosolic Ca
2+
 (Mark et al. 2001, Wang and Qin 2010). Stresses, 
potentially due to malaoxon causing a Ca
2+
 influx on the mitochondria and endoplasmic 
reticulum, include increases in membrane depolarisation, release of pro-apoptotic 
factors and Ca
2+
 uptake (Dong et al. 2009, Ward et al. 2000). Disturbance in 
mitochondrial membrane potential due to Ca
2+
 influx can negatively affect respiration, 
ROS production, activation of pro-apoptotic caspases including caspase 3 and 9, ATP 
synthesis and therefore energy availability making the cell more vulnerable to insult, 
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autophagy and apoptosis (McIlwain et al. 2015, Porter and Janicke 1999, Wang and Qin 
2010, Ward et al. 2000). This is reflected in the data due to the decrease seen in cell 
viability, presence of dead cells, and changes seen in glutamate, carbohydrates and fatty 
acids (discussed below).  
 
Glutamate can be metabolised into other amino acids including glutamine, arginine, 
proline, alanine and aspartate that can be further converted into other amino acids 
(KEGG, http://www.genome.jp/kegg/). This may be a protective mechanism against 
glutamate excitotoxicity which would account for the decrease in glutamate levels. As 
aerobic respiration is affected by damage to the mitochondria, the cells may be utilising 
other energy sources, which include amino acids, in order to repair damage, as well as 
the synthesis of new proteins, potentially accounting for the decrease in amino acids.  
Serine has been shown to have antioxidant and protective effects in other cell types, and 
as previously discussed, metabolism of serine is associated with nucleotide synthesis, 
therefore serine might be part of the recovery process (de Koning et al. 2003, Maralani 
et al. 2012). In contrast, serine metabolism may also be contributing to neuronal injury 
and death. It has been demonstrated that the excitotoxic response increases expression 
and activity of an enzyme that converts ceramide from serine, and ceramide can 
contribute to disruption of the mitochondrial membrane potential, causing release of 
cytochrome c and activation of caspases (Ong et al. 2010).  
Levels of carbohydrates and fatty acids also decreased; therefore glycolysis and 
potentially β-oxidation may have been overstimulated as a response to cellular stress in 
order to try and protect the cell against damage. In addition, fatty acids may also be 
utilised in the process of repairing damage to the cell membrane. This indicates that the 
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cell may have been in the process of repairing the neurotoxic damage and stress caused 
by malaoxon exposure. 
4.3.2.2 RA-differentiated/malaoxon 
As previously mentioned, when SH-SY5Y cells were exposed to RA and malaoxon, 
there was an increase in the majority of amino acid metabolites deemed important by 
PCA. As glutamate had increased, this potentially indicates that an excitotoxic response 
had occurred, and was different to the response of glutamate in control/maloxon, 
indicating that RA may have affected the process. It could have responded this way if 
the toxicity caused by malaoxon was to a lesser extent and therefore glutamate was not 
converted to other amino acids as a protective response. Lower overall cellular stress 
may have allowed levels of the other amino acids to be maintained, or they may have 
recovered within 24 hours, as amino acids may not have been required for energy 
metabolism or protein synthesis due to lower toxicity. In RA-treated/malaoxon cells, 
serine was not considered to be an important metabolite and therefore may not have 
been required for the recovery process. This may indicate a lower level of toxicity as 
serine has potential antioxidant and protective effects, and is required for nucleotide 
synthesis (de Koning et al. 2003, Maralani et al. 2012). This potentially indicates a 
decreased toxic response to malaoxon when the cells have been differentiated with RA, 
enabling cells to recover more quickly. This is reflected in the cell count and 
morphology data as RA-treated/malaoxon had a higher viability and fewer dead cells 
present.  
The levels of carbohydrates in RA-treated/malaoxon cells decreased, but fatty acids 
increased. This also indicates that a toxic response had occurred as carbohydrates 
decreased in control/malaoxon as a result of cellular stress stimulating metabolism, 
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which may also be occurring here as part of the recovery process. An increase in fatty 
acids suggests, in agreement with the increases in amino acids, that alternative energy 
sources may not be required as mitochondrial damage may have been lessened if a 
reduced toxic effect occurred. Fatty acids may also be increased as they were not being 
utilised to repair cell membranes due to lower production of ROS and therefore lipid 
peroxidation, which agrees with cholesterol having decreased.  
Repetition of this study would require at least 10 counts for each treatment group, and 
the use of an appropriate cytotoxicity assay. This assay would itself require 
optimisation, multiple concentrations, and multiple time points in order to see the effect 
on undifferentiated and differentiated cells. The experiment was limited by the fact that 
the only concentration of malaoxon used was low, and exposure was only for 24 hours. 
Therefore we cannot determine the changes that have occurred over time. Expansion of 
this study would further elucidate the potential protective mechanism facilitated by RA.  
In spite of these limitations, the aim associated with this portion of the study was 
achieved as the biochemical response of undifferentiated and differentiated SH-SY5Y 
cells to malaoxon was investigated. The collective investigations indicate that a toxic 
biochemical response had occurred due to malaoxon exposure, and that there may have 
been a potential protective effect of RA due to lesser toxicity or a quicker recovery 
period. GC-MS metabolomic analysis could be used to discover these changes as the 
biochemical changes induced resulted in metabolite profiles that were different from the 
control. The use of this technique is a novel approach to study this process as previous 
studies have focused on upstream changes involving an individual or group of genes 
and proteins, whereas this study has determined changes to the metabolome which are 
closer to the phenotype of a RA-differentiated cell and therefore what actually occurred 
in the cell.  
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4.4 Pathway Analysis 
The biochemical pathways suggested by this study as being involved in RA-induced 
differentiation and/or malaoxon toxicity are summarised in Figures 4.1 and 4.2. The 
process of excitotoxicity involves the activity of a number of enzymes, transcription 
factors and signalling molecules that have been shown to also be involved in the process 
of RA-induced differentiation. This includes the PI cycle involved in production of 
second messengers, and NF-κB and JNK, which have both been shown to be part of the 
RA-induced differentiation process (Feng and Porter 1999, Kim et al. 2005, Yu et al. 
2003). RA also induces accumulation of ceramide and activation of metalloproteinases, 
PKC, ERK1/ERK2 and CREB (Feng et al. 1994, Hemmings and Restuccia 2012, Kim 
et al. 2005, Lee et al. 2012, Miloso et al. 2004, Singh et al. 2003, Tanaka et al. 2012). 
ERK1/ERK2 signalling pathways have been noted as regulating numerous neuronal 
processes, including differentiation and cell death, and therefore this proposed dual role 
of the MAP kinases suggests that activation can occur via several different pathways 
(Skaper et al. 2001). These similarities potentially indicate that both malaoxon-induced 
excitotoxicity and RA-induced differentiation require some of the same pathways, 
proteins, enzymes and transcription factors for each process to occur. The different 
response seen in undifferentiated and differentiated cells exposed to malaoxon suggests 
that the biochemical changes initiated by differentiation were primarily via these 
pathways. 
This is supported by the data as some of the factors induced by RA differentiation were 
likely inducing a potential survival/neuroprotective response. A key pathway stimulated 
by RA-induced differentiation is PI3K/Akt, which has been shown to be crucial for the 
process of differentiation, protein synthesis and in cell survival due to its ability to 
inactivate pro-apoptotic proteins including bad and caspase 9, and to activate CREB 
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which can subsequently activate pro-survival genes (Hemmings and Restuccia 2012, 
Skaper et al. 2001, Vara et al. 2004, Zhou et al. 2000). Caspase 9 was shown to increase 
after excitotoxicity, indicating differentiation may counteract this process and limit 
apoptosis and necrosis. Bcl-2, whose levels are increased by RA differentiation, has 
been shown to prevent the release of cytochrome c from the mitochondria which was 
seen to increase in excitotoxicity, thereby decreasing apoptosis and changing the 
vulnerability of the cells to insult (Tieu et al. 1999, Zhou et al. 2000). PKC and 
ERK1/ERK2 have also been shown to be required for cell survival (Miloso et al. 2004), 
and were activated in the excitotoxicity process (Skaper et al. 2001).  
Survival and neuroprotective responses have been demonstrated by a number of studies 
comparing undifferentiated and RA-differentiated cells. RA-differentiated cells, in 
comparison to undifferentiated cells, have been shown to be less susceptible to 
glutamate toxicity, as seen by an increase in cell viability after RA-differentiation 
(Nampoothiri et al. 2014). Nampoothiri et al. (2014) suggest RA-differentiation causes 
up-regulation of survival signalling and decreased susceptibility to neurotoxins. Lau 
(2007) and Cheung et al. (2009) discussed that RA differentiation resulted in increased 
resistance to oxidative stress, including when exposed to the parkinsonian mimetic 
toxins 1-methyl-4-phenylpyridium (MPP
+
) and 6-hydroxydopamine (6-OHDA), due to 
RA activating survival signalling. They both suggest that RA-induced activation of the 
PI3K/Akt pathway is responsible for the observed neuroprotection (Cheung et al. 2009). 
Schneider et al. (2011) demonstrated resistance to toxicity and mitochondrial 
dysfunction in RA differentiated cells in relation to the reactive lipid species 4-
hydroxynonenal (HNE) and the ROS generator 2,3-dimethoxy-1,4-naphthoquinone 
(DMNQ). They suggest resistance is attributed to RA increasing the mitochondrial 
membrane potential, levels of cytochrome c, manganese superoxide dismutase 
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(MnSOD), and the bioenergetic reserve capacity (Schneider et al. 2011). Increasing the 
bioenergetic reserve capacity may contribute to recovery from stressors such as 
increased Ca
2+
 levels, ROS and RNS, increasing energy to repair protein and lipids, in 
comparison to undifferentiated cells (Schneider et al. 2011). Lasorella et al. (1995) and 
Tieu et al. (1999) also indicated increased resistance in RA differentiated cells due to 
exposure to 6-OHDA, 5-fluorouracil, cisplatin and adriamycin (Adr), all of which 
induce apoptosis. They suggest an increased in Bcl-2 can contribute to changes in cell 
vulnerability and resistance.  
These studies discuss that both undifferentiated and differentiated SH-SY5Y cells are 
commonly used in neuroscience and in particular neurotoxic research (Cheung et al. 
2009, Lasorella et al. 1995, Schneider et al. 2011, Tieu et al. 1999). Results such as 
those discussed in this study in relation to survival suggest that undifferentiated cells 
may be more appropriate for the study of certain neurotoxins as the differentiated 
phenotype can mask the actual toxicity of a compound, indicating caution should be 
taken when using RA-differentiated cells to model neurotoxic processes due to changes 
in neurotoxicity, survival and apoptotic response. 
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Figure 4.1 Proposed mechanism of RA-induced differentiation in SH-SY5Y cells. These changes have 
affected the metabolism of amino acids, carbohydrates and fatty acids. Green indicates pathways that 
may induce neuroprotective response against malaoxon exposure. Red indicates pathways also 
activated in excitotoxicity. 
Affected amino acid, carbohydrate 
and fatty acid metabolism 
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Figure 4.2 Proposed mechanism of neurotoxicity in SH-SY5Y cells exposed to malaoxon. 
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4.5 Limitations and expansions 
An initial study such as this is crucial in the development of robust experimental design 
in order to produce reproducible methods. Limitations therefore need to be addressed 
and incorporated in future studies. A limitation of this experiment was the fact that only 
intracellular samples were used for metabolomic analysis. Analysis of the extracellular 
medium was not carried out due to the high concentration of glucose in the media, 
which interferes with GC-MS analysis. Future studies should modify the methodology 
to allow analysis of extracellular samples, which will allow us to better understand the 
biochemical changes occurring with differentiation and exposure. As considered earlier 
in the discussion, the passage number of the cells, the number of replicates, and 
supplementation of the media are all factors that would need to be considered in future 
experimentation.  
In terms of the instrumental analysis, both GC- and LC-based approaches could be used 
in order to expand metabolome coverage, as this would give a more comprehensive 
analysis encompassing more metabolic pathways. In addition, within the processes of 
extraction and derivatisation, there is the possibility of loss of some metabolites, 
especially those that are volatile. This may have reduced the range of metabolites 
profiled in this analysis. In future, this may require further optimisation or incorporation 
of different techniques. The sensitivity of detection in this analysis may also be a 
limitation that could be corrected with the incorporation of more sensitive 
instrumentation such as triple quadrupole (QQQ) GC-MS, which would also provide 
further metabolome coverage. An untargeted analysis was utilised for this study as it 
allows detection of a broad range of metabolites in a single analysis. Data from this and 
related studies may allow targeted analysis of important metabolites to be carried out in 
future experiments giving more detailed information on changes to specific pathways. 
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Expansion of the in-house metabolite library is currently underway and will contribute 
to the identification of metabolites in future analyses, including unknowns that were 
identified as part of this untargeted analysis, which would enhance our interpretation of 
the data.  
4.6 Conclusion 
The overall aim of this study was to investigate the biochemical response of RA-
induced differentiation and the effect of malaoxon on undifferentiated and RA-
differentiated SH-SY5Y neuroblastoma cells. Previous studies have focused on 
upstream changes on a single or group of genes or proteins, which is not sufficiently 
definitive to outline downstream biochemical functions. It was anticipated that 
metabolomics analysis would provide novel insight into the changes in downstream 
biochemistry (the metabolome), that most reflect modifications in the phenotype. This 
would help assess whether GC-MS metabolomics could be used to analyse the 
biochemical changes associated with RA-differentiation and malaoxon exposure, and 
whether differentiated cells are more appropriate for future toxicology research. 
The results from this preliminary study show that GC-MS-based metabolomic analysis 
produced distinct metabolite profiles and identified biochemical pathway modifications 
associated with undifferentiated and RA-differentiated cells, also exposed to malaoxon. 
Further analysis is required to more definitively identify the pathways that are part of 
the RA differentiation process, particularly those related to apoptosis and survival. 
However, the data from this study does demonstrate that GC-MS metabolomic analysis 
can be used to study the range of metabolic changes associated with RA differentiation, 
and with exposure to malaoxon.  
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The observable trends detected in metabolites indicate that there were a range of 
biochemical changes associated with using RA to differentiate SH-SY5Y cells, and that 
the potential glutamate-mediated toxicity induced by malaoxon may be less in RA-
differentiated cells due to induction of a neuroprotective response mediated by survival 
and apoptotic regulation. This different response to the neurotoxin suggests that using 
RA-differentiated cells in neuroscience research should be done with caution. In some 
cases, undifferentiated cells may be more appropriate for the study of certain 
neurotoxins as the differentiated phenotype can mask the actual toxicity of a compound.  
RA differentiation is a complex process inducing a range of changes to the metabolome. 
Future studies would enhance our understanding of the effects of this process on cellular 
metabolism, which is important as SH-SY5Y cells are widely used in neuroscience, in 
particular to model toxic processes. Having appropriate cell models is crucial to produce 
accurate outcomes in research and we have demonstrated that there are a range of 
biochemical changes that occur during RA differentiation that may affect the response 
of cells to neurotoxins.   
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